



Europass Curriculum Vitae

Personal information

First name(s) / Surname(s) **Gianluigi Savarese**

Desired employment / Occupational field **Associate Professor of Cardiology
Division of Cardiology, Department of Medicine
Karolinska Institute, Stockholm, Sweden**

**Cardiology Consultant and Heart Failure Specialist
Heart and Vascular Theme
Karolinska University Hospital, Stockholm, Sweden**

Dates Title of qualification awarded	2024 – ongoing Secretary of the Heart Failure Association of the European Society of Cardiology
Dates Title of qualification awarded	April 2020 – Ongoing Cardiology Consultant/Heart Failure Specialist Karolinska University Hospital and Karolinska Institutet
Dates Title of qualification awarded	October 2020 – ongoing Associate Professor of Cardiology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden
Dates Title of qualification awarded	2020 – ongoing Board Member of the Heart Failure Association of the European Society of Cardiology
Dates Title of qualification awarded	2018-2020 Secretary of the Working Group of Cardiovascular Pharmacotherapy of the European Society of Cardiology
Dates Title of qualification awarded	April 2018 – May 2019 Assistant Professor of Cardiology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden
Dates Title of qualification awarded	March 2018 PhD – Title thesis “Biomarkers for eligibility and surrogate endpoints in heart failure trials” – Cardiology, Department of Medicine, Karolinska Institutet
Dates Title of qualification awarded	October 2017 Specialist in Heart Failure - Postgraduate degree in Heart Failure by European Society of Cardiology, University of Zurich, Switzerland
Dates Title of qualification awarded	June 30th, 2016 Specialist in Cardiology – Postgraduate School of Cardiology, Federico II University, Naples, Italy
Dates Title of qualification awarded	June 2016 – August 2024 Nucleus Member of the Working Group on Cardiovascular Pharmacotherapy of European Society of Cardiology

Dates	July 1 st 2013 – December 31 st 2014
Title of qualification awarded	Research fellow at Center for Molecular Cardiology, University of Zurich, Zurich.
Dates	June 2012 - ongoing
Title of qualification awarded	AIFA (Agenzia Italiana del Farmaco) Expert
Dates	2011
Title of qualification awarded	Medical Board, Medical Association of Naples
Dates	October 21 th , 2010
Title of qualification awarded	Graduated in Medicine and Surgery at the “Federico II” University of Naples summa cum laude.
Dates	2004
Title of qualification awarded	Graduated from “G. Salvemini” Scientific School of Sorrento (Naples)(score 100/100)

Personal skills and competences

Mother tongue(s) **Italian**

Other language(s) **English (certified)**

Self-assessment

European level ()*

Language

Understanding				Speaking				Writing	
Listening		Reading		Spoken interaction		Spoken production			
C1	Independent User	C1	Independent User	C1	Independent User	C1	Independent User	C1	Independent User

Swedish: C1 (certified)
German: A2

Organisational skills and competences

Fellow of Rotary Club Sorrento (2013 - 2016)(Rotary International)
President of Rotaract Club Castellammare-Sorrento (2010-2011)(Rotary International),
Secretary of Rotaract Club Castellammare-Sorrento (2009-2010)(Rotary International),
President of Interact Club Sorrento (2003-2004)(Rotary International)

Computer skills and competences

Computer and Statistical skills: Optimal command of STATA statistical software, SPSS statistical software.

Statistical Competences: Advanced level (survival analysis, regression analyses, interactions, propensity score matching, multiple imputation, etc)

Lab Competences: FELASA certification, left anterior descending coronary ligation in mice and rats, heart catheterization in mice and rats, cardiac magnetic resonance in mice and rats, western blotting, cell culture, ELISA

GCP training (October 2021)

MEMBERSHIPS AND FELLOWSHIPS

- 2010 Member of the Italian Society of Cardiology (SIC)
- 2014 Fellow of the European Society of Cardiology Fellowship (FESC).
- 2015 Fellow in training of the American College of Cardiology (ACC FIT)
- 2015 Member of the Heart Failure Association (European Society of Cardiology)
- 2015 Member of the Working Group of Pharmacotherapy of the European Society of Cardiology
- 2016 Member of the Surveys, Registry and Epidemiology Committee of the Heart Failure Association (HFA) – European Society of Cardiology (ESC).
- 2016 Fellowship of the Heart Failure Association - European Society of Cardiology Fellowship (FHFA).
- 2018 Scholar of the Italian Society of Cardiology

AWARDS and GRANTS

- 2012 **ARCA** (Associazioni Regionali Cardiologi Extraospedalaieri) **Award** for the research entitled “Effetti del diabete mellito di tipo II sulla funzione microvascolare e sulla perfusione miocardica in pazienti ipertesi senza coronaropatia ostruttiva. Uno studio di scintigrafia perfusionale e doppler transtoracico”.
- 2012 **Best Poster Award ESC12** for the research entitled: 6-minute walk distance and clinical events in pulmonary arterial hypertension: a meta-analysis of 22 randomized studies. (ESC Congress 2012, Munich August 25-29, 2012).
- 2013 **ESC (European Society of Cardiology) Research Grant** (25000 euros) spent at the Department of Cardiology and Zurich Heart House and Foundation for Cardiovascular Research; University Hospital Zurich and Careum Campus Zurich. 1 July 2013 – 30 June 2014.
- 2013 **Premio "Giovane Ricercatore" – Young investigator award from the Italian Society of Cardiology** for the research entitled: La terapia guidata dai livelli dei peptidi natriuretici nello scompenso cardiaco cronico: una meta-analisi di 2686 pazienti e 12 trials randomizzati.
- 2015 **Premio Giovane Ricercatore SICOA** (Società Italiana Cardiologia Ospedalità Accreditata) – **Young investigator award from SICOA society**
- 2016 **SIC (Italian Society of Cardiology) and MSD ITALIA-MERCK SHARP & DOHME CORPORATION grant for research periods abroad** (25000 euros), spent at the Department of Medicine, Karolinska Institutet, Stockholm, Sweden (September 1st 2016 – August 31st 2017)
- 2016 **Hjärt-Lungfondens Travel Grant (9000 kr - ≈ 1000 euros)** spent at the European Society of Cardiology Congress 2016 in Rome.
- 2016 **Hjärt-Lungfondens Travel Grant (18000 kr - ≈ 18000 euros)** spent at the Scientific Sessions 2016 of American Heart Association in New Orleans, USA.
- 2017 **Hjärt-Lungfondens Travel Grant (9000 kr - ≈ 1000 euros)** spent at the Heart Failure and the World Congress on Acute Heart Failure (HFA), Paris, France.
- 2017 **Hjärt-Lungfondens Travel Grant (9000 kr - ≈ 1000 euros)** spent at the European Society of Cardiology (ESC) Congress 2017, Barcelona, Spain.
- 2017 **Young Investigator Award on Population Science from European Society of Cardiology (finalist - 1000 Euros)**
- 2018 **Hjärt-Lungfondens Travel Grant (18000 kr - 1800 euros)** spent at the American College of Cardiology Congress 2018, Orlando, USA
- 2018 **Hjärt-Lungfondens Travel Grant (9000 kr - ≈ 1000 euros)** spent at the HFA Congress, Vienna, Austria
- 2018 **Italian Ministry of Education, Universities and Research. CoPI Ricerca Finalizzata (390000 euros)**
Title of the project “Non-coding RNAs and myocardial fibrosis in patients with acute coronary syndrome: impact on left ventricular remodeling”.
- 2018 **Hjärt-Lungfondens Travel Grant (409.500 kr - ≈ 41000 euros).**
Project title: Heart failure with preserved and mid-range ejection fraction - importance of proper characterization for future interventional trials.

- 2018 **Young Investigator Award on Population Science from the Heart Failure Association of the European Society of Cardiology (finalist)**
- 2018 **Advanced fellowship in cardiovascular clinical trials (CVCT forum – Boehringer Ingelheim)**
- 2019 Investigator driven project supported by AstraZeneca: 1.200.000 SEK (around 120.000 Euros)
Use of the Inhibitors of sodium–glucose cotransporter 2 in patients with Heart Failure and Type 2 Diabetes Mellitus
- 2019 Investigator driven project supported by Vifor: 500.000 SEK (≈ 50.000 Euros)
Real world evidence study to assess chronic heart failure patients with iron deficiency/anemia in terms of specific patterns of iron treatment and health care outcomes
- 2019 Investigator driven project supported by Novartis: 70.000 USD
Eligibility for sacubitril/valsartan in heart failure across the ejection fraction spectrum.
- 2020 Investigator initiated project supported by Boston Scientific: 110.800 Euros
Contemporary effectiveness of cardiac resynchronization therapy and implantable cardioverter defibrillator in patients with heart failure with reduced ejection fraction: data from the Swedish Heart Failure Registry
- 2020 Investigator initiated project supported by Pharmacosmos: 708.000 SEK (≈ 70.000 Euros)
Phenotyping heart failure patients with iron deficiency (2020-2021)
- 2020 Investigator initiated project supported by Boehringer Ingelheim: 557.500 SEK (≈ 55.000 Euros)
Use of care in heart failure patients across the ejection fraction spectrum (2020-2021)
- 2020 Grant from AstraZeneca: 500.000 SEK (≈ 48.000 Euros)
Awareness of indications and current practice in use of heart failure treatments: A survey study(2020-2022)
- 2021 Investigator initiated project supported by Merck 885.000 SEK (85.000 Euros)
A registry study of N-terminal pro-B-type natriuretic peptide (NT-proBNP) in patients with heart failure, with a focus on worsening heart failure, in Sweden
- 2022 Investigator initiated project supported by Bayer 67.500 Euros
Eligibility for Vericiguat in real-world heart failure patients: data from the Swedish Heart Failure Registry
- 2022 EU Horizon 2020: ≈320.000 Euros (2022-2027)
A European Health Data Toolbox for Enhancing Cardiology Data Interoperability, Reusability and Privacy

ATTENDANCE AT NATIONAL AND INTERNATIONAL MEETINGS AS SPEAKER

1. **La disfunzione endoteliale è associata alla malattia coronarica e correla con il controllo glicemico in pazienti con diabete mellito di tipo 2.**
70° Congresso Nazionale della Società Italiana di Cardiologia. Roma, 12-15 December 2009
2. **Regressione dell'ipertrofia ventricolare sinistra ed eventi cardiovascolari. Una Metanalisi.**
71° Congresso Nazionale della Società Italiana di Cardiologia. Roma, 11-13 December 2010
3. **Does 6-minute walk test predict clinical events in pulmonary arterial hypertension? A meta-analysis of 22 studies.** ACC.12, 61st Annual Scientific Session and Expo, Chicago.
4. **Do changes in pulmonary hemodynamics predict clinical events in pulmonary arterial hypertension? A meta-analysis of 17 studies.** ACC.12, 61st Annual Scientific Session and Expo, Chicago.
5. **Do changes of brain natriuretic and n-terminal pro-b-type natriuretic peptides predict cardiovascular events in heart failure patients? A meta-analysis of 27 trials in 15,820 patients.**
ACC.12, 61st Annual Scientific Session and Expo, Chicago.
6. **I bisogni insoddisfatti della cardiopatia ischemica.** Napoli, 21-22 Giugno 2012
7. **Pulmonary hemodynamic changes, functional capacity and clinical events in pulmonary arterial hypertension. A meta-analysis of 16 randomized trials.**
ESC Congress 2012. Munich, 25-29 August 2012.
8. **6-minute walk distance and clinical events in pulmonary arterial hypertension: a meta-analysis of 22 randomized studies.**
ESC Congress 2012. Munich, 25-29 August 2012.
9. **Effects of atorvastatin and rosuvastatin on renal function in patients at high cardiovascular risk: a meta-analysis of 21 randomized trials.**
ESC Congress 2012. Munich, 25-29 August 2012.
10. **The prognostic rule of brain natriuretic and N-terminal pro-B-type natriuretic peptides changes in heart failure. A meta-regression study of 25 randomized trials in 15,722 patients.**
ESC Congress 2012. Munich, 25-29 August 2012.
11. **Left Ventricular Hypertrophy Reduction and Clinical Events. A Meta-regression Analysis of 14 Studies in 12,809 Hypertensive Patients.**
AHA Scientific Session 2012. Los Angeles, 3-7 November 2012.
12. **Effects of Atorvastatin and Rosuvastatin on Renal Function: A Meta-analysis.**
AHA Scientific Session 2012. Los Angeles, 3-7 November 2012.
13. **Effects of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers on Mortality and Cardiovascular Events in Patients Without Heart Failure. A Meta-Analysis of Randomized Clinical Trials in 108,233 patients.**
AHA Scientific Session 2012. Los Angeles, 3-7 November 2012.
14. **Do Changes of Urinary Albumin Excretion Predict Cardiovascular Events? A Meta-regression Analysis of 32 Randomized Trials.**
AHA Scientific Session 2012. Los Angeles, 3-7 November 2012.

15. **Iperтроfia ventricolare sinistra ed eventi clinici. Una meta-analisi di 14 studi e 12809 pazienti ipertesi.**
73° Congresso Nazionale della Società Italiana di Cardiologia. Roma, 15-17 December 2012
16. **Effetti degli inibitori dell'enzima di conversione dell'angiotensina e dei bloccanti del recettore dell'angiotensina sulla mortalità e sugli eventi cardiovascolari in pazienti senza scompenso cardiaco.**
73° Congresso Nazionale della Società Italiana di Cardiologia. Roma, 15-17 December 2012
17. **Acido urico ed eventi cardiovascolari: una meta-analisi di 11 studi randomizzati**
73° Congresso Nazionale della Società Italiana di Cardiologia. Roma, 15-17 December 2012
18. **Ruolo prognostico delle variazioni dei livelli plasmatici del peptide natriuretico cerebrale e del segmento N-terminale del precursore del peptide natriuretico cerebrale nello scompenso cardiaco.**
73° Congresso Nazionale della Società Italiana di Cardiologia. Roma, 15-17 December 2012
19. **Variazioni dell'emodinamica del circolo polmonare, capacità funzionale ed eventi clinici nell'ipertensione arteriosa polmonare. Una meta-analisi di 16 studi randomizzati.**
73° Congresso Nazionale della Società Italiana di Cardiologia. Roma, 15-17 December 2012
20. **Test dei 6 minuti ed eventi clinici nell'ipertensione arteriosa polmonare: una meta-analisi di 22 studi randomizzati.**
73° Congresso Nazionale della Società Italiana di Cardiologia. Roma, 15-17 December 2012
21. **Albuminuria ed eventi cardiovascolari: una meta-analisi di 31 studi randomizzati**
73° Congresso Nazionale della Società Italiana di Cardiologia. Roma, 15-17 December 2012
22. **Effetti dell'atorvastatina e della rosuvastatina sulla funzione renale in pazienti ad alto rischio cardiovascolare: una meta-analisi di 21 studi randomizzati**
73° Congresso Nazionale della Società Italiana di Cardiologia. Roma, 15-17 December 2012
23. **Changes of urinary albumin excretion and cardiovascular events: a meta-regression analysis of 32 randomized trials and 80,812 patients.**
ESC Congress 2013. Amsterdam, 31 Aug – 4 Sep 2013.
24. **Natriuretic peptide-guided therapy in chronic heart failure: a meta-analysis of 2,686 patients in 12 randomized trials.**
ESC Congress 2013. Amsterdam, 31 Aug – 4 Sep 2013.
25. **Benefits of statins in elderly subjects without established cardiovascular disease. a meta-analysis.**
ESC Congress 2013. Amsterdam, 31 Aug – 4 Sep 2013.
26. **Prognostic Impact of Metabolic Syndrome in Patients With Chronic Heart Failure: Data From Gissi-Hf Trial**
AHA Scientific Session 2013. Dallas, 16 - 20 November 2013.
27. **Effects of Ranolazine in Symptomatic Patients With Stable Coronary Artery Disease. A Meta-analysis of Randomized Clinical Trials**
AHA Scientific Session 2013. Dallas, 16 - 20 November 2013.
28. **Prognostic Impact of Body Weight Change in Patients With Chronic Heart Failure: Data From Gissi-Hf Trial**
AHA Scientific Session 2013. Dallas, 16 - 20 November 2013.
29. **La terapia guidata dai livelli dei peptidi natriuretici nello scompenso cardiaco cronico: una meta-analisi di 2686 pazienti e 12 trials randomizzati**

74° Congresso Nazionale della Società Italiana di Cardiologia. Roma, 14-16 December 2013

30. Effetti della Ranolazina nei pazienti sintomatici con cardiopatia ischemica cronica. Una meta-analisi di trials randomizzati

74° Congresso Nazionale della Società Italiana di Cardiologia. Roma, 14-16 December 2013

31. Benefici del trattamento con statine nei soggetti anziani in prevenzione primaria. Una meta-analisi

74° Congresso Nazionale della Società Italiana di Cardiologia. Roma, 14-16 December 2013

32. A meta-analysis reporting effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients without heart failure.

74° Congresso Nazionale della Società Italiana di Cardiologia. Roma, 14-16 December 2013.

33. Prognostic impact of metabolic syndrome in patients with chronic heart failure: data from GISSI-HF trial

ESC Congress 2014. Barcelona, 29 Aug – 2 Sep 2014

34. Reduction of C-reactive protein is associated with reduced risk of myocardial infarction. A meta-analysis of 16 randomized trials

ESC Congress 2014. Barcelona, 29 Aug – 2 Sep 2014

35. Exacerbated aging of cerebral arteries is mediated by the adaptor protein p66Shc

ESC Congress 2014. Barcelona, 29 Aug – 2 Sep 2014

36. Changes of natriuretic peptides predict hospital admissions in patients with chronic heart failure. A meta-analysis

ESC Congress 2014. Barcelona, 29 Aug – 2 Sep 2014

37. Cardiovascular Effects of Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients: A Meta-Analysis of 95 Trials.

AHA Scientific Session 2014. Chicago, 15-19 Nov 2014

38. Markers of cardiovascular risk and organ damage

75° Congresso Nazionale della Società Italiana di Cardiologia. Roma, 13-15 December 2014.

39. Impatto prognostico della sindrome metabolica nei pazienti con scompenso cardiaco cronico: nuove evidenze dal trial gissi-hf

75° Congresso Nazionale della Società Italiana di Cardiologia. Roma, 13-15 December 2014.

40. La riduzione della proteina c reattiva non è associata ad una riduzione del rischio cardiovascolare e della mortalità nei pazienti trattati con statine. Una meta-analisi di 22 studi randomizzati.

75° Congresso Nazionale della Società Italiana di Cardiologia. Roma, 13-15 December 2014.

41. Benefits of statins in elderly subjects without established cardiovascular disease. A meta-analysis.

75° Congresso Nazionale della Società Italiana di Cardiologia. Roma, 13-15 December 2014.

42. Efficacy and Safety of Novel Oral Anticoagulants in Patients with Atrial Fibrillation and Heart Failure: A Meta-Analysis of Phase III Clinical Trials.

ACC.15, 64th Annual Scientific Session and Expo. San Diego, 14-16 March 2015.

43. Nuove strategie nella gestione del rischio cardiovascolare

Congresso Nazionale SICOA (Società Italiana Cardiologia Ospedalità Accreditata) 2015. Giardini Naxos (ME) 14-17 May 2015

44. Systematic Reviews and Meta-Analysis

All About Clinical Trial Course by Working Group on Cardiovascular Pharmacology of European Society of Cardiology. Rome, 29-30 May 2015

45. Comparative associations between angiotensin converting enzyme inhibitors, angiotensin receptor blockers and their combination, and outcomes in patients with heart failure and reduced ejection fraction

ESC Congress 2015, London, 29 August – 2 September 2015

46. Novel oral anticoagulants in patients with atrial fibrillation and heart failure: a meta-analysis

ESC Congress 2015, London, 29 August – 2 September 2015

47. Systematic Reviews and Meta-Analysis

All About Clinical Trial Course by Working Group on Cardiovascular Pharmacology of European Society of Cardiology. Barcelona, 23-24 October 2015

48. Observational Studies and Registries

All About Clinical Trial Course by Working Group on Cardiovascular Pharmacology of European Society of Cardiology. Barcelona, 23-24 October 2015

49. Changes in N-terminal Pro Brain Natriuretic Peptide Levels Predicts Mortality and Heart Failure Hospitalization in Patients With Heart Failure and Preserved Ejection Fraction

AHA Scientific Sessions 2015. Orlando, 7-11 November 2015

50. Benefits and Safety of Prolonged Dual Antiplatelet Therapy in Patients With Ischemic Cardiovascular Disease: A Meta-analysis of 18 Randomized Trials Including 94,306 Patients

AHA Scientific Sessions 2015. Orlando, 7-11 November 2015

51. Changes of natriuretic peptides predict hospital admissions in patients with chronic heart failure

76° Congresso Nazionale della Società Italiana di Cardiologia. Roma, 11-14 December 2015.

52. Systematic Reviews and Meta-Analysis

All About Clinical Trial Course by Working Group on Cardiovascular Pharmacology of European Society of Cardiology. Brussels, 18-19 March 2016

53. Observational Studies and Registries

All About Clinical Trial Course by Working Group on Cardiovascular Pharmacology of European Society of Cardiology. Brussels, 18-19 March 2016

54. Changes in N-terminal Pro Brain Natriuretic Peptide Levels Predicts Mortality and Heart Failure Hospitalization in Patients With Heart Failure and Preserved Ejection Fraction

ACC.16, 65th Annual Scientific Session and Expo. Chicago, 2-4 April 2016.

55. Mortality in patients exposed to Digoxin: a meta-analysis

Heart Failure and the World Congress on Acute Heart Failure (HFA). Florence, 21-24 May 2016.

56. Efficacy and safety of novel oral anticoagulants in patients with atrial fibrillation and heart failure: a meta-analysis.

Heart Failure and the World Congress on Acute Heart Failure (HFA). Florence, 21-24 May 2016.

57. Efficacy and safety of dipeptidyl peptidase 4 inhibitors in patients with type 2 diabetes mellitus: a meta-analysis of 116 trials.

Heart Failure and the World Congress on Acute Heart Failure (HFA). Florence, 21-24 May 2016.

58. Systematic Reviews and Meta-Analysis

All About Clinical Trial Course by Working Group on Cardiovascular Pharmacology of European Society of Cardiology. Tel Aviv, 29-30 May 2016

59. Observational Studies and Registries

All About Clinical Trial Course by Working Group on Cardiovascular Pharmacology of European Society of Cardiology. Tel Aviv, 29-30 May 2016

60. Mortality and morbidity in heart failure patients exposed to Digoxin: comprehensive data according to ejection fraction and atrial fibrillation in 41881 patients from the Swedish Heart Failure Registry

ESC Congress 2016. Rome, 27-31 August 2016.

61. Efficacy and safety of dipeptidyl peptidase 4 inhibitors and sodium-glucose linked cotransporter-2 inhibitors in patients with type 2 diabetes mellitus: a meta-analysis

ESC Congress 2016. Rome, 27-31 August 2016.

62. Systematic Reviews and Meta-Analysis

All About Clinical Trial Course by Working Group on Cardiovascular Pharmacology of European Society of Cardiology. London, 30 September - 1 October 2016

63. Observational Studies and Registries

All About Clinical Trial Course by Working Group on Cardiovascular Pharmacology of European Society of Cardiology. London, 30 September - 1 October 2016

64. Changes in Natriuretic Peptides After Hospitalization for Heart Failure With Preserved Ejection Fraction: A Feasible Surrogate Endpoint? A Report From the Prospective Karen Study

AHA Scientific Sessions 2016. New Orleans, USA, 11-15 November 2016

65. Systematic Reviews and Meta-Analysis

All About Clinical Trial Course by Working Group on Cardiovascular Pharmacology of European Society of Cardiology. Berlin, 9-10 December 2016

66. Observational Studies and Registries

All About Clinical Trial Course by Working Group on Cardiovascular Pharmacology of European Society of Cardiology. Berlin, 9-10 December 2016

67. Mortality and Morbidity in Patients With Heart Failure and Reduced Ejection Fraction Exposed to Digoxin: Comprehensive Data According to Atrial Fibrillation in 23,708 Patients From the Swedish Heart Failure Registry

ACC.17, 66th Annual Scientific Session and Expo. Washington, 17-19 March 2017.

*Highlights session

68. Systematic Reviews and Meta-Analysis

All About Clinical Trial Course by Working Group on Cardiovascular Pharmacology of European Society of Cardiology. Brussels, 10-11 March 2017

69. Observational Studies and Registries

All About Clinical Trial Course by Working Group on Cardiovascular Pharmacology of European Society of Cardiology. Brussels, 10-11 March 2017

70. Digoxin, friend or foe in heart failure - the latest evidence

19 Svenska Kardiovaskulära Vårmetet, Malmö, Sweden

71. Use of mineralocorticoid receptor antagonists in a real-world population with heart failure and reduced ejection fraction: an analysis of 24,529 patients from the swedish heart failure registry

Heart Failure and the World Congress on Acute Heart Failure (HFA). Paris, 29 April - 2 May 2017

72. Oral anticoagulant use in patients with atrial fibrillation and concomitant heart failure: an analysis of 22,719 patients from the swedish heart failure registry

Heart Failure and the World Congress on Acute Heart Failure (HFA). Paris, 29 April - 2 May 2017

73. Systematic Reviews and Meta-Analysis

EuroCVP 2017 - All About Clinical Trial Course by Working Group on Cardiovascular Pharmacology of European Society of Cardiology. Rome, 26-28 May 2017

74. Observational Studies and Registries

EuroCVP 2017 - All About Clinical Trial Course by Working Group on Cardiovascular Pharmacology of European Society of Cardiology. Rome, 26-28 May 2017

75. Cardiovascular risk in diabetics

EuroCVP 2017 by Working Group on Cardiovascular Pharmacology of European Society of Cardiology. Rome, 26-28 May 2017

76. Clinical trial design and statistical methods

ESC Congress 2017. Barcelona, 26-30 August 2017

77. Impact of CHA2DS2-VASc and HAS-BLED SCORES on oral anticoagulant use and outcomes in patients with atrial fibrillation and concomitant heart failure: an analysis of 22,055 patients from the SwedeHF (finalist Young Investigator Award on Population Science)

ESC Congress 2017. Barcelona, 26-30 August 2017

78. Patterns and prognostic role of N-terminal pro-B-type Natriuretic Peptide in heart failure with mid-range vs. preserved vs. reduced ejection fraction

ESC Congress 2017. Barcelona, 26-30 August 2017

79. Interpreting Meta-Analyses and Clinical Trials: Can we Believe the Data?

ICCAD 2017 – Innovations in coronary artery disease. Venice, 15-17 October 2017

80. Systematic Reviews and Meta-Analysis

All About Clinical Trial Course by Working Group on Cardiovascular Pharmacology of European Society of Cardiology. Vienna, 8-9 December 2017

81. Observational Studies and Registries

All About Clinical Trial Course by Working Group on Cardiovascular Pharmacology of European Society of Cardiology. Vienna, 8-9 December 2017

82. Interpreting meta-analyses and clinical trials: can we believe the data?

All About Clinical Trial Course by Working Group on Cardiovascular Pharmacology of European Society of Cardiology. Vienna, 8-9 December 2017

83. Systematic Reviews and Meta-Analysis

All About Clinical Trial Course by Working Group on Cardiovascular Pharmacology of European Society of Cardiology. Brussels, 2-3 February 2018

84. Observational Studies and Registries

All About Clinical Trial Course by Working Group on Cardiovascular Pharmacology of European Society of Cardiology. Brussels, 2-3 February 2018

85. Interpreting meta-analyses and clinical trials: can we believe the data?

All About Clinical Trial Course by Working Group on Cardiovascular Pharmacology of European Society of Cardiology. Brussels, 2-3 February 2018

- 86. Predictors of and outcomes associated with referral to a heart failure nurse-led clinic: an analysis of 40,992 patients from the Swedish Heart Failure Registry**
ACC.18, 67th Annual Scientific Session and Expo. Orlando, 10-12 March 2018.
- 87. Unmet needs in heart failure in 2018**
Annual meeting of the Russian working group on cardiovascular pharmacotherapy. Moscow, 21 April 2018
- 88. Association between renin-angiotensin system inhibitor use and morality/morbidity in elderly patients with heart failure with reduced ejection fraction: a prospective propensity score-matched cohort – Late breaking trial session**
Heart Failure and the World Congress on Acute Heart Failure (HFA). Vienna, 26-29 May 2018
- 89. Incidence of dyskalemia in heart failure with preserved, mid-range, and reduced ejection fraction: an analysis of 6401 patients from the Swedish Heart Failure registry**
Heart Failure and the World Congress on Acute Heart Failure (HFA). Vienna, 26-29 May 2018
- 90. Heart failure with recovered EF**
Heart failure 2030. Pisa, 23-24 April 2018
- 91. Optimizing patient selection in heart failure trials: the role of NT-proBNP**
ESC Congress 2018. Munich, 31 August – 4 September 2018.
- 92. Systematic Reviews and Meta-Analysis**
All About Clinical Trial Course by Working Group on Cardiovascular Pharmacology of European Society of Cardiology. Lisbon, 12-13 October 2018
- 93. Observational Studies and Registries**
All About Clinical Trial Course by Working Group on Cardiovascular Pharmacology of European Society of Cardiology. Lisbon, 12-13 October 2018
- 94. An overview of the different aspects of clinical trials**
All About Clinical Trial Course by Working Group on Cardiovascular Pharmacology of European Society of Cardiology. Lisbon, 12-13 October 2018
- 95. Postmarketing surveillance**
All About Clinical Trial Course by Working Group on Cardiovascular Pharmacology of European Society of Cardiology. Lisbon, 12-13 October 2018
- 96. Randomized controlled trials and subgroup analyses**
All About Clinical Trial Course by Working Group on Cardiovascular Pharmacology of European Society of Cardiology. Lisbon, 12-13 October 2018
- 97. Potential of real-world data analysis**
proCardio2018. Madrid 29-30 October 2018
- 98. Systematic Reviews and Meta-Analysis**
All About Clinical Trial Course by Working Group on Cardiovascular Pharmacology of European Society of Cardiology. Vienna, 8-9 December 2018
- 99. Observational Studies and Registries**
All About Clinical Trial Course by Working Group on Cardiovascular Pharmacology of European Society of Cardiology. Vienna, 8-9 December 2018

100. An overview of the different aspects of clinical trials

All About Clinical Trial Course by Working Group on Cardiovascular Pharmacology of European Society of Cardiology. Vienna, 8-9 December 2018

101. Postmarketing surveillance

All About Clinical Trial Course by Working Group on Cardiovascular Pharmacology of European Society of Cardiology. Vienna, 8-9 December 2018

102. Management of peripheral arterial disease

The Year in Cardiology. Dubai, 22-24 February 2019

103. Update on the ESC guidelines on arterial hypertension

The Year in Cardiology. Dubai, 22-24 February 2019

104. Empagliflozin is associated with a lower risk of post-acute heart failure re-hospitalization and mortality: insights from the EMPA-REG outcome trial

ACC.19, 68th Annual Scientific Session and Expo. New Orleans, 16-18 March 2019.

105. A case of a patient with chronic kidney disease and hyperkalemia: how to optimise RAAS inhibitors?

Heart Failure and the World Congress on Acute Heart Failure (HFA). Athens, 25-28 May 2019

106. Association between beta-blocker use and mortality/morbidity in elderly patients with heart failure with reduced ejection fraction: a prospective propensity score-matched study – Late breaking trial Science

ESC Congress 2019. Paris, 31 August – 4 September 2019.

107. How to optimize RAASi therapy in patients with hyperkalemia.

HFA Webinars 2020. 19 March 2020.

108. Eligibility for sacubitril/valsartan in heart failure across the ejection fraction spectrum: real world data from the Swedish Heart Failure Registry.

HFA Discoveries – Late Breaking Science 2 – Registries. 5 June 2020.

109. Patient preferences for newer oral therapies in type 2 diabetes

European Association for the Study of Diabetes (EASD) congress 2020. Virtual. 22 June 2020.

110. How to select anti-hypertensive agents in older patients – ACE and ARBs in the COVID-19 pandemic

EuroCVP 2021. Annual congress of the WG on Cardiovascular Pharmacotherapy of the European Society of Cardiology. Virtual. 10-12 June 2021.

111. Observational studies and registries

EuroCVP 2021. Annual congress of the WG on Cardiovascular Pharmacotherapy of the European Society of Cardiology. Virtual. 10-12 June 2021.

112. Systematic reviews and meta-analyses

EuroCVP 2021. Annual congress of the WG on Cardiovascular Pharmacotherapy of the European Society of Cardiology. Virtual. 10-12 June 2021.

113. Best paper of the European Journal of Heart Failure – epidemiology, biomarkers and imaging.

Heart Failure and the World Congress on Acute Heart Failure (HFA) 2021. Virtual. 29 June- 1 July 2021

114. Eligibility for dapagliflozin and empagliflozin in real-world heart failure based on DAPA-HF,

DELIVER, EMPEROR-Reduced and EMPEROR-Preserved selection criteria.

Heart Failure and the World Congress on Acute Heart Failure (HFA) 2021. Virtual. 29 June- 1 July 2021

115. Heart Failure Drug Titration, Discontinuation and Mortality and HF Hospitalization Risk: A Multinational Observational Study (US, UK and Sweden)

Heart Failure and the World Congress on Acute Heart Failure (HFA) 2021. Virtual. 29 June- 1 July 2021

116. Quando usare I nuovi anticoagulanti nel paziente con SCC - solo quando il pz è in FA.

Heart Failure and the World Congress on Acute Heart Failure (HFA) 2021. Virtual. 29 June- 1 July 2021

117. OMT in the real world: clinical and administrative registries.

Heart Failure and the World Congress on Acute Heart Failure (HFA) 2021. Virtual. 29 June- 1 July 2021

118. Implenting HF treatments in clinical practice

Heart Failure Summit. Cairo. 23-24 September 2021

119. Kidney Disease and Heart Failure

Heart Failure Program. Dubai. 10-11 September 2021

120. Treatment approaches in HFpEF

Heart Failure Program. Dubai. 10-11 September 2021

121. Registry-based research in HF

HFA Clinical Trial in Heart Failure Course 2021. Sorrento (Italy). 1-3 October 2021

122. Different designs of meta-analysis (aggregated data, IP, network, bayesian vs. frequentist)

HFA Clinical Trial in Heart Failure Course 2021. Sorrento (Italy). 1-3 October 2021

123. Co-morbidities in HF affecting QoL and hard outcomes: CKD

E-space Heart Failure 2021. Virtual. 8-10 October 2021

124. Implementation of HF treatments

Cardiology: a contemporary outlook. Stockholm. 11-12 November 2021

125. Pathophysiology of HFpEF

Device in HF (D-HF) 2021. Frankfurt. 10-11 December 2021

SCIENTIFIC WORKS

1. Perrone-Filardi P, Costanzo P, Dellegrottaglie S, Gargiulo P, Ruggiero D, **Savarese G**, Parente A, D'Amore C, Cuocolo A, Chiariello M.

Prognostic role of myocardial single photon emission computed tomography in the elderly

Journal of Nuclear Cardiology 2010;17:310-5.

2. Monda C, Scala O, Paolillo S, **Savarese G**, Cecere M, D'Amore C, Parente A, Musella F, Mosca S, Filardi PP.
Sleep apnea and heart failure: pathophysiology, diagnosis and therapy.
G Ital Cardiol 2010;11:815-22.
3. Filardi PP, Cecere M, **Savarese G**, Damore C, Parente A, Conte S, Coutsoumbas G.
Inflammation and lipids in the coronary pathology. Risk factors, causes or therapeutic target?
G Ital Cardiol 2010;11(12 Suppl 3):10S-15S.
4. Prastaro M, Paolillo S, **Savarese G**, Dellegrottaglie S, Scala O, Ruggiero D, Gargiulo P, Marciano C, Parente A, Cecere M, Musella F, Chianese D, Scopacasa F, Perrone-Filardi P.
N-terminal pro-b-type natriuretic peptide and left atrial function in patients with congestive heart failure and severely reduced ejection fraction.
Eur J Echocardiogr 2011;12:506-513.
5. Gargiulo P, Petretta M, Bruzzese D, Cuocolo A, Prastaro M, D'Amore C, Vassallo E, **Savarese G**, Marciano C, Paolillo S, Filardi PP.
Myocardial perfusion scintigraphy and echocardiography for detecting coronary artery disease in hypertensive patients: a meta-analysis.
Eur J Nucl Med Mol Imaging 2011;38:2040-9.
6. Gargiulo P, Marciano C, **Savarese G**, D'Amore C, Paolillo S, Esposito G, Santomauro M, Marsico F, Ruggiero D, Scala O, Marzano A, Cecere M, Casaretti L, Perrone Filardi P.
Endothelial dysfunction in type 2 diabetic patients with normal coronary arteries A digital reactive hyperemia study.
Int J Cardiol 2013;165:67-71.
7. Perrone-Filardi P, Paolillo S, Dellegrottaglie S, Gargiulo P, **Savarese G**, Marciano C, Casaretti L, Cecere M, Musella F, Pirozzi E, Parente A, Cuocolo A.
Assessment of cardiac sympathetic activity by MIBG imaging in patients with heart failure: a clinical appraisal.
Heart 2011;97:1828-33.
8. Marsico F, **Savarese G**, Sardu C, D'Ascia C, Ruggiero D, Casaretti L, Parisi V, Musella F, Pirozzi E, Formisano R, Losco T, Filardi, PP
Implantable cardioverter defibrillator to prevent sudden cardiac death in a patient with systemic sclerosis: A clinical case
Journal of Cardiology Cases 2012;5:e166-e170.
9. Perrone-Filardi P, **Savarese G**, Rengo G, Mattiello G, Leosco D.
Viability and left ventricular dysfunction: what changes after STICH?
G Ital Cardiol 2012;13:81-3.
10. **Savarese G**, Losco T, Parente A, Musella F, Pirozzi E, Mosca S, Casaretti L, Formisano R, Conte S, Bologna A, Mattiello G, Perrone-Filardi P.
Clinical applications of MIBG SPECT in chronic heart failure
G Ital Cardiol 2012;13:91-7.
11. **Savarese G**, Paolillo S, Costanzo P, D'Amore C, Cecere M, Losco T, Musella F, Gargiulo P, Marciano C, Perrone-Filardi P.
Do changes of 6-minute walk distance predict clinical events in patients with pulmonary arterial hypertension? A meta-analysis of 22 randomized trials
J Am Coll Cardiol 2012;60:1192-201.

12. Perrone-Filardi P, Musella F, **Savarese G**, Cecere M, Marciano C, Scala O, MD1, Rengo G, Dellegrottaglie S, Cuocolo A, Leosco D.
Coronary computed tomography: current role and future perspectives for cardiovascular risk stratification.
Eur Heart J Cardiovasc Imaging 2012;13:453-8.
13. Marciano C, Galderisi M, Gargiulo P, D'Amore C, Esposito R, Cuocolo A, **Savarese G**, Casaretti L, Lo Iudice F, Esposito G, Rengo G, Leosco D, MD, Perrone-Filardi P.
Effects of type 2 diabetes mellitus on microvascular function and myocardial perfusion in patients without obstructive coronary artery disease. A perfusion scintigraphy and doppler transthoracic study.
Eur J Nucl Med Mol Imag 2012;39:1199-206.
14. **Savarese G**, Musella F, Volpe M, MD, Paneni F, Perrone-Filardi P.
Effects of atorvastatin and rosuvastatin on renal function: a meta-analysis.
Int J Cardiol 2013;167:2482-9.
15. **Savarese G***, Costanzo P*, Rosano G, Musella F, Casaretti L, Vassallo E, Paolillo S, Marsico F, Rengo G, Leosco D, Perrone-Filardi P.
Left ventricular hypertrophy reduction and clinical events. A meta-regression analysis of 14 studies in 12,809 hypertensive patients.
Int J Cardiol. 2013;167:2757-64.
*Equally contribution
16. Ruggiero D, **Savarese G**, Formisano R, Bologna A, Mattiello G, Pirozzi E, Gambardella F, Lo Iudice F, Petraglia L, Vitagliano A, Casaretti L, Della Ratta GL, Mosca S, Filardi PP.
Endothelial dysfunction in type 2 diabetic patients with normal coronary arteries. A peripheral arterial tonometry study.
Monaldi Arch Chest Dis 2012;78:34-9.
17. **Savarese G**, Costanzo P, Cleland JGF, Vassallo E, Ruggiero D, Rosano G, Perrone-Filardi P,
A Meta-Analysis Reporting Effects of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Patients Without Heart Failure.
J Am Coll Cardiol 2013;61:131-42
18. **Savarese G**, Musella F, D'Amore C, Losco T, Marciano C, Gargiulo P, Rengo G, Dellegrottaglie S, Bossone E, Leosco D, Perrone-Filardi P
Hemodynamics, functional capacity and clinical events in pulmonary arterial hypertension.
Eur Respir J 2013;42:414-24.
19. Rosano MCG, Spoleitini I, **Savarese G**, Perrone-Filardi P.
Endogenous sex hormones are associated with blood pressure change and hypertension incidence in postmenopausal women.
Clin Lipidol 2012;7:617-620.
20. Rengo G, Pagano G, Squizzato A, Moja L, Femminella GD, de Lucia C, Komici K, Parisi V, **Savarese G**, Ferrara N, Perrone-Filardi P, Leosco D.
Oral anticoagulation therapy in heart failure patients in sinus rhythm: a systematic review and meta-analysis.
PLoS ONE 8(1): e52952. doi:10.1371/journal.pone.0052952
21. Bossone E, **Savarese G**, Ferrara F, Citro R, Mosca S, Musella F, Limongelli G, Manfredini R, Cittadini A, Perrone-Filardi P
Takotsubo cardiomyopathy: overview
Heart Fail Clin 2013;9:249-66. doi: 10.1016/j.hfc.2012.12.015.

22. Paolillo S, Rengo G, Pagano G, Pellegrino T, **Savarese G**, Femminella GD, Tuccillo M, Boemio A, Attena E, Formisano R, Petraglia L, Scopacasa F, Galasso G, Leosco D, Trimarco B, Cuocolo A, Perrone-Filardi P.
Impact of diabetes mellitus on cardiac sympathetic innervation in patients with heart failure. A iodine-123 meta-iodobenzylguanidine (I123MIBG) scintigraphic study.
Diabetes Care 2013;36:2395-401.
23. **Savarese G**, Trimarco B, Dellegrottaglie S, Prastaro M, Gambardella F, Rengo G, Leosco D, Perrone-Filardi P.
Natriuretic peptide-guided therapy in chronic heart failure: a meta-analysis of 2,686 patients in 12 randomized trials.
PLoS ONE 2013;8(3):e58287. doi:10.1371/journal.pone.0058287.
24. **Savarese G**, Ferri C, Trimarco B, Rosano G, Dellegrottaglie S, Losco T, Casaretti L, D'Amore C, Gambardella F, Prastaro M, Rengo G, Leosco D, Perrone-Filardi P.
Changes of serum uric acid levels and cardiovascular events. A meta-analysis.
Nutr Metab Cardiovasc Dis 2013;23:707-14.
25. Marsico M, Ruggiero D, Parente A, Pirozzi E, Musella F, Lo Iudice F, **Savarese G**, Losco T, Giugliano G, Rengo G, Dellegrottaglie S, Leosco D, Esposito G, Trimarco B, Perrone Filardi P.
Prevalence and severity of asymptomatic coronary and carotid artery disease in patients with lower limbs arterial disease.
Atherosclerosis 2013;228:386-9.
26. Dellegrottaglie S, Guarini P, **Savarese G**, Gambardella F, Iudice FL, Cirillo A, Vitagliano A, Formisano T, Pellegrino AM, Bossone E, Perrone-Filardi P.
Cardiac magnetic resonance for the assessment of myocardial viability: from pathophysiology to clinical practice.
J Cardiovasc Med (Hagerstown) 2013;14:862-9.
27. Gargiulo P, Dellegrottaglie S, Bruzzese D, **Savarese G**, Scala O, Ruggiero D, D'Amore C, Paolillo S, Agostoni Piergiuseppe, Bossone E, Soricelli A, Cuocolo A, Trimarco B, Perrone Filardi P.
The Prognostic Value of Normal Stress Cardiac Magnetic Resonance in Patients with Known or Suspected Coronary Artery Disease: A Meta-analysis
Circ Cardiovasc Imaging 2013;6:574-82.
28. **Savarese G**, Gotto AM Jr, Paolillo S, D'Amore C, Losco T, Musella F, Scala O, Marciano C, Ruggiero D, Marsico F, De Luca G, Trimarco B, Perrone-Filardi P.
Benefits of statins in elderly subjects without established cardiovascular disease. A meta-analysis
J Am Coll Cardiol 2013;62:2090-9.
29. **Savarese G**, Rosano G, D'Amore C, Musella F, Della Ratta GL, Pellegrino AM, Formisano T, Vitagliano A, Cirillo A, Cice G, Fimiani L, Del Guercio L, Trimarco B, Perrone-Filardi P.
Effects of ranolazine in symptomatic patients with stable coronary artery disease. A systematic review and meta-analysis.
Int J Cardiol 2013;169:262-70.
30. **Savarese G**, Dei Cas A, Rosano G, D'Amore C, Musella F, Mosca S, Reiner MF, Marchioli R, Trimarco B, Perrone-Filardi P.
Reduction of albumin urinary excretion is associated with reduced cardiovascular events in hypertensive and/or diabetic patients. A meta-regression analysis of 32 randomized trials.
Int J Cardiol. 2014;172:403-10.
31. **Savarese G**, Musella F, D'Amore C, Vassallo E, Losco L, Gambardella F, Cecere M, Petraglia L, Pagano G, Fimiani L, Rengo G, Leosco D, Trimarco B, Perrone-Filardi P.

Changes of natriuretic peptides predict hospital admissions in patients with chronic heart failure
JACC Heart Fail 2014;2:148-58.

32. **Savarese G**, Perrone-Filardi P.
Reply to Letter to the Editor: "Benefits of Statins in Elderly Subjects Without Established Cardiovascular Disease"
J Am Coll Cardiol. 2014 Jun 3;63(21):2303.
33. **Savarese G***, Shi Y*, Perrone-Filardi P, Lüscher TF, Camici GG.
Enhanced age-dependent cerebrovascular dysfunction is mediated by adaptor protein p66Shc.
Int J Cardiol 2014;175:446-50.
*Equally contribution
34. Gargiulo P, Cuocolo A, Dellegrottaglie S, Prastaro M, **Savarese G**, Assante R, Zampella E, Paolillo S, Scala O, Ruggiero D, Marsico F, Perrone Filardi P.
Nuclear Assessment of Right Ventricle.
Echocardiography 2015;32 Suppl 1:S69-74.
35. **Savarese G**, Rosano GMC, Parente A, D'Amore C, Reiner MF, Camici GG, Trimarco B, Perrone-Filardi P.
Reduction of C-reactive protein is not associated with reduced cardiovascular risk and mortality in patients treated with statins. A meta-analysis of 22 randomized trials.
Int J Cardiol 2014;177:152-60.
36. Reiner MF, Martinod K, Stivala S, **Savarese G**, Camici GG, Lüscher TF, Wagner DD, Beer JH.
Dietary omega-3 alpha-linolenic acid does not prevent venous thrombosis in mice.
Thromb Haemost. 2015;113:177-84.
37. Prastaro M, D'Amore C, Paolillo S, Losi M, Marciano C, Perrino C, Ruggiero D, Gargiulo P, **Savarese G**, Trimarco B, Perrone Filardi P.
Prognostic role of transthoracic echocardiography in patients affected by heart failure and reduced ejection fraction.
Heart Fail Rev 2015;20:305-16.
38. **Savarese G.**
Vitamin D and parathyroid hormone: a new piece in the puzzle of cardiovascular risk.
J Cardiovasc Med (Hagerstown) 2015;16:71.
39. **Savarese G***, Perrone-Filardi P*, Scarano M, Cavazzina R, Trimarco B, Minneci S, Maggioni AP, Tavazzi L, Tognoni G, Marchioli R.
Prognostic impact of metabolic syndrome in patients with chronic heart failure: Data from GISSI-HF trial.
Int J Cardiol. 2014 Oct 23;178C:85-90
*Equally contribution
40. **Savarese G**, Perrone-Filardi P, D'Amore C, Vitale C, Trimarco B, Pani L, Rosano GM.
Cardiovascular effects of dipeptidyl peptidase-4 inhibitors in diabetic patients: A meta-analysis.
Int J Cardiol 2014;181C:239-244.
41. Paolillo S, Rengo G, Pellegrino T, Formisano R, Pagano G, Gargiulo P, **Savarese G**, Carotenuto R, Petraglia L, Rapacciuolo A, Perrino C, Piscitelli S, Attena E, Del Guercio L, Leosco D, Trimarco B, Cuocolo A, Perrone-Filardi P.
Insulin resistance is associated with impaired cardiac sympathetic innervation in patients with heart failure.
Eur Heart J Cardiovasc Imaging. 2015;16:1148-53.

42. Spescha RD, Klohs J, Semerano A, Giacalone G, Derungs RS, Reiner MF, Rodriguez Gutierrez D, Mendez-Carmona N, Glanzmann M, **Savarese G**, Kränkel N, Akhmedov A, Keller S, Mocharla P, Kaufmann MR, Wenger RH, Vogel J, Kulic L, Nitsch RM, Beer JH, Peruzzotti-Jametti L, Sessa M, Lüscher TF, Camici GG.
Post-ischaemic silencing of p66Shc reduces ischaemia/reperfusion brain injury and its expression correlates to clinical outcome in stroke.
Eur Heart J 2015;36:1590-1600.
43. Perrone-Filardi P, Paolillo S, Costanzo P, **Savarese G**, Trimarco B, Bonow RO.
The role of metabolic syndrome in heart failure.
Eur Heart J 2015;36:2630-4.
44. **Savarese G**, Edner M, Dahlström U, Perrone-Filardi P, Hage C, Cosentino F, Lund LH.
Comparative associations between angiotensin converting enzyme inhibitors, angiotensin receptor blockers and their combination, and outcomes in patients with heart failure and reduced ejection fraction.
Int J Cardiol. 2015;199:415-423.
45. **Savarese G**, De Ferrari GM, Rosano GMC, Perrone-Filardi P.
Safety and efficacy of ezetimibe: a meta-analysis
Int J Cardiol 2015;201:247-52.
46. Camici GG, **Savarese G**, Akhmedov A, Lüscher TF.
Molecular mechanism of endothelial and vascular aging: implications for cardiovascular disease.
Eur Heart J 2015;36:3392-403
47. **Savarese G**, Perrone-Filardi P.
Reply to: Ezetimibe: A real effect?
Int J Cardiol 2016;209:337-8.
48. **Savarese G**, Savonitto S, Lund LH, Paolillo S, Marciano C, Dellegrottaglie S, Parente A, Trimarco B, Luscher TF, Perrone-Filardi P
Efficacy and safety of prolonged dual antiplatelet therapy: a meta-analysis of 15 randomized trials enrolling 85 265 patients
Eur Heart J Cardiovasc Pharmacother 2016;2:218-28.
49. Giamundo A, Canciello G, Rapacciuolo A, Musella F, **Savarese G**, Strisciuglio T, Stabile E, Izzo R, Trimarco B, Losi MA.
Comparison of linear versus cubic assessment of left atrial size in the prediction of atrial fibrillation development in hypertrophic cardiomyopathy.
Int J Cardiol 2016; 212:198-200.
50. **Savarese G**, Giugliano RP, Rosano GMC, McMurray J, Magnani G, Filippatos G, Dellegrottaglie S, Lund LH, Trimarco B, Perrone-Filardi P.
Efficacy and safety of novel oral anticoagulants in patients with atrial fibrillation and heart failure: a meta-analysis
JACC Heart Fail. 2016 Nov;4(11):870-880.
51. Ricci F, Di Castelnuovo A, **Savarese G**, Perrone Filardi P, De Caterina R.
ACE-inhibitors versus angiotensin receptor blockers for prevention of events in cardiovascular patients without heart failure - A network meta-analysis.
Int J Cardiol. 2016 Apr 29;217:128-134.
52. Rapacciuolo A, Perrone Filardi P, Cuomo R, Mauriello V, Quarto M, Kisslinger A, **Savarese G**, Illario M, Tramontano D.

The impact of social and cultural engagement and dieting on well-being and resilience in a group of residents in the metropolitan area of Naples.

J Aging Res. 2016;2016:4768420

53. **Savarese G, D'Amore C, Federici M, De Martino F, DelleGrottaglie S, Marciano C, Ferrazzano F, Losco T, Lund LH, Trimarco B, Rosano GM, Perrone-Filardi P.**
Effects of Dipeptidyl Peptidase 4 Inhibitors and Sodium-Glucose Linked coTransporter-2 Inhibitors on cardiovascular events in patients with type 2 diabetes mellitus: A meta-analysis.
Int J Cardiol. 2016 Jun 27;220:595-601.
54. **Merlini M, Shi Y, Keller S, Savarese G, Akhmedov A, Derungs R, Spescha RD, Kulic L, Nitsch R, Lüscher T, Camici G.**
Reduced nitric oxide bioavailability mediates cerebroarterial dysfunction independent of cerebral amyloid angiopathy in a mouse model of Alzheimer's disease.
Am J Physiol Heart Circ Physiol. 2016 Nov 11:ajpheart.00607.2016. doi: 10.1152/ajpheart.00607.2016.
55. **Savarese G, Donal E, Hage C, Oger E, Persson H, Daubert JC, Linde C, Lund LH; KaRen investigators**
Changes in natriuretic peptides after acute hospital presentation for heart failure with preserved ejection fraction: A feasible surrogate trial endpoint? A report from the prospective Karen study.
Int J Cardiol. 2016 Oct 17;226:65-70.
56. **Savarese G, Lund LH, Rosano GM.**
Incretin-based therapy for type 2 diabetes: A real class effect?
Int J Cardiol. 2016 Nov 9;227:141-142.
57. **Savarese G, Hage C, Orsini Nm Dahlstrom U, Perrone-Filardi P, Rosano MCG, Lund LH**
Reductions in N-Terminal Pro-Brain Natriuretic Peptide Levels Are Associated With Lower Mortality and Heart Failure Hospitalization Rates in Patients With Heart Failure With Mid-Range and Preserved Ejection Fraction
Circ Heart Fail 2016; doi: dx.doi.org/10.1161/CIRCHEARTFAILURE.116.003105
58. **Reiner MF, Akhmedov A, Stivala S, Keller S, Gaul DS, Bonetti NR, Savarese G, Glanzmann M, Zhu C, Ruf W, Yang Z, Matter CM, Lüscher TF, Camici GG, Beer JH.**
Ticagrelor, but not clopidogrel, reduces arterial thrombosis via endothelial tissue factor suppression.
Cardiovasc Res 2017;113:61-69.
59. **Reiner MF, Breitenstein A, Holy EW, Glanzmann M, Amstalden H, Stämpfli SF, Bonetti NR, Falk V, Keller S, Savarese G, Benussi S, Maisano F, Lüscher TF, Beer JH, Steffel J, Camici GG.**
Ticagrelor, but not clopidogrel active metabolite, displays antithrombotic properties in the left atrial endocardium.
Eur Heart J. 2017 Jan 8. pii: ehw578. doi: 10.1093/eurheartj/ehw578.
60. **Savarese G, Lund LH.**
Digoxin: Beneficial or Harmful?
Eur Heart J Cardiovasc Pharmacother. 2017 Feb 16. doi: 10.1093/ehjcvp/pvx004.
61. **Tamargo J, Rosano G, Thomas W, Duarte J, Niessner A, Kaski JC, Cecconi C, Drexel H, Kjeldsen K, Savarese G, Torp-Pedersen C, Atar D, Lewis BS, Agewall S.**
Gender differences in the effects of cardiovascular drugs.
Eur Heart J Cardiovasc Pharmacother. 2017 Feb 28. doi: 10.1093/ehjcvp/pvw042.
62. **Prastaro M, Pirozzi E, Gaibazzi N, Paolillo S, Santoro C, Savarese G, Losi MA, Esposito G, Perrone Filardi P, Trimarco B, Galderisi M.**
Expert Review on the Prognostic Role of Echocardiography after Acute Myocardial Infarction.
J Am Soc Echocardiogr. 2017 May;30(5):431-443.e2.

63. Vedin O, Lam CSP, Koh AS, Benson L, Teng THK, Tay WT, Braun OÖ, **Savarese G**, Dahlström U, Lund LH.
Significance of Ischemic Heart Disease in Patients With Heart Failure and Preserved, Midrange, and Reduced Ejection Fraction: A Nationwide Cohort Study.
Circ Heart Fail. 2017 Jun;10(6). pii: e003875.
64. **Savarese G**, Lund LH.
Global Public Health Burden of Heart Failure.
Card Fail Rev. 2017 Apr;3(1):7-11.
65. **Savarese G***, Das D*, Dahlström U, Fu M, Howlett J, Ezekowitz JA, Lund LH.
Ivabradine in Heart Failure: The Representativeness of SHIFT (Systolic Heart Failure Treatment With the IF Inhibitor Ivabradine Trial) in a Broad Population of Patients With Chronic Heart Failure.
Circ Heart Fail. 2017 Sep;10(9). pii: e004112
*Equally contribution
66. Koh AS, Tay WT, Teng THK, Vedin O, Benson L, Dahlstrom U, **Savarese G**, Lam CSP, Lund LH.
A comprehensive population-based characterization of heart failure with mid-range ejection fraction.
Eur J Heart Fail. 2017 Sep 25. doi: 10.1002/ejhf.945.
67. **Savarese G**, Lund LH.
Up-titrating angiotensin-converting enzyme inhibitors in heart failure: evidence and challenges.
Eur J Heart Fail. 2017 Oct 5. doi: 10.1002/ejhf.978.
68. Niessner A, Tamargo J, Koller L, Saely CH, Schmidt TA, **Savarese G**, Wassmann S, Rosano G, Ceconi C, Torp-Pedersen C, Kaski JC, Kjeldsen KP, Agewall S, Walther T, Drexel H, Lewis BS.
Non-insulin antidiabetic pharmacotherapy in patients with established cardiovascular disease: a position paper of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy.
Eur Heart J. 2017 Nov 8. doi: 10.1093/eurheartj/ehx625
69. **Savarese G**, Lund LH.
Ticagrelor versus prasugrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention: An unresolved issue.
Int J Cardiol. 2017 Dec 15;249:77-78.
70. **Savarese G***, Gargiulo P*, D'Amore C, De Martino F, Lund LH, Marsico F, Dellegrottaglie S, Marciano C, Trimarco B, Perrone-Filardi P.
Efficacy and safety of glucagon-like peptide-1 agonists on macrovascular and microvascular events in type 2 diabetes mellitus: A meta-analysis.
Nutr Metab Cardiovasc Dis. 2017 Sep 28. pii: S0939-4753(17)30221-1.
*Equally contribution
71. Lund LH, Vedin O, **Savarese G**.
Is ejection fraction in heart failure a limitation or an opportunity?
Eur J Heart Fail. 2018 Jan 15. doi: 10.1002/ejhf.1106.
72. Hemingway H, Asselbergs FW, Danesh J, Dobson R, Maniadakis N, Maggioni A, van Thiel GJ, Cronin M, Brobert G, Vardas P, Anker SD, Grobbee DE, Denaxas S; **BigData@Heart Consortium** .
Big data from electronic health records for early and late translational cardiovascular research: challenges and potential.
Eur Heart J. 2017 Aug 29. doi: 10.1093/eurheartj/ehx487.

73. **Savarese G, Sartipy U, Friberg L, Dahlström U, Lund LH.**
Reasons for and consequences of oral anticoagulant underuse in atrial fibrillation with heart failure.
Heart. 2018 Jan 25. pii: heartjnl-2017-312720. doi: 10.1136/heartjnl-2017-312720
74. **Savarese G, Orsini N, Hage C, Vedin O, Cosentino F, Rosano GMC, Dahlström U, Lund LH.**
Using NT-proBNP for Eligibility and Enrichment in Trials in HFpEF, HFmREF, and HFrEF.
JACC Heart Fail. 2018 Feb 1. pii: S2213-1779(18)30039-8. doi: 10.1016/j.jchf.2017.12.014.
75. **Savarese G, Carrero JJ, Pitt B, Anker SD, Rosano GMC, Dahlstrom U, Lund LH**
Factors associated with underuse of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction: an analysis of 11 215 patients from the Swedish Heart Failure Registry
Eur J Heart Fail 2018; doi: 10.1002/ejhf.1182
76. **Savarese G, Orsini N, Hage C, Dahlström U, Vedin O, Rosano GMC, Lund LH.**
Associations With and Prognostic and Discriminatory Role of N-Terminal Pro-B-Type Natriuretic Peptide in Heart Failure With Preserved Versus Mid-range Versus Reduced Ejection Fraction.
J Card Fail 2018. pii: S1071-9164(18)30123-4. doi: 10.1016/j.cardfail.2018.03.010.
77. Rosano GMC, Tamargo J, Kjeldsen KP, Lainscak M, Agewall S, Anker SD, Ceconi C, Coats AJS, Drexel H, Filippatos G, Kaski JC, Lund L, Niessner A, Ponikowski P, **Savarese G**, Schmidt TA, Seferovic P, Wassmann S, Walther T, Lewis BS.
Expert consensus document on the management of hyperkalaemia in patients with cardiovascular disease treated with renin angiotensin aldosterone system inhibitors: coordinated by the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology.
Eur Heart J Cardiovasc Pharmacother. 2018 Jul 1;4(3):180-188.
78. **Savarese G, D'Amario D.**
Sex Differences in Heart Failure.
Adv Exp Med Biol. 2018;1065:529-544. doi: 10.1007/978-3-319-77932-4_32.
79. Akhmedov A, Bonetti NR, Reiner MF, Spescha RD, Amstalden H, Merlini M, Gaul DS, Diaz-Cañestro C, Spescha RS, Semerano A, Giacalone G, **Savarese G**, Montecucco F, Kulic L, Nitsch RM, Matter CM, Kullak-Ublick GA, Sessa M, Lüscher TF, Beer JH, Liberale L, Camici GG.
Deleterious role of endothelial lectin-like oxidized low-density lipoprotein receptor-1 in ischaemia/reperfusion cerebral injury.
J Cereb Blood Flow Metab. 2018 Aug 3:271678X18793266. doi: 10.1177/0271678X18793266.
80. **Savarese G, Vasko P, Jonsson Å, Edner M, Dahlström U, Lund LH.**
The Swedish Heart Failure Registry: a living, ongoing quality assurance and research in heart failure.
Ups J Med Sci. 2018 Aug 9:1-5. doi: 10.1080/03009734.2018.1490831.
81. Vonbank A, Drexel H, Agewall S, Lewis BS, Dopheide JF, Kjeldsen K, Ceconi C, **Savarese G**, Rosano G, Wassmann S, Niessner A, Schmidt TA, Saely CH, Baumgartner I, Tamargo J.
Reasons for disparity in statin adherence rates between clinical trials and real-world observations: a review.
Eur Heart J Cardiovasc Pharmacother. 2018 Oct 1;4(4):230-236.
82. **Savarese G, Dahlström U, Vasko P, Pitt B, Lund LH**
Association between renin-angiotensin system inhibitor use and mortality/morbidity in elderly patients with heart failure with reduced ejection fraction: a prospective propensity score-matched cohort study
Eur Heart J. 2018 Oct 22. doi: 10.1093/eurheartj/ehy621.

83. Cooper LB, **Savarese G**, Carrero JJ, Szabo B, Jernberg T, Jonsson Å, Dahlbom C, Dahlström U, Larson A, Lund LH.
Clinical and research implications of serum versus plasma potassium measurements.
Eur J Heart Fail. 2018 Nov 28. doi: 10.1002/ehhf.1371
84. **Savarese G**, Xu H, Trevisan M, Dahlström U, Rossignol P, Pitt B, Lund LH, Carrero JJ.
Incidence, Predictors, and Outcome Associations of Dyskalemia in Heart Failure With Preserved, Mid-Range, and Reduced Ejection Fraction.
JACC Heart Fail. 2019 Jan;7(1):65-76.
85. Galli M, Andreotti F, **Savarese G**, D'Amario D, Vergallo R, Della Bona R, Caló L, Porto I, Crea F
Dropping aspirin in patients with atrial fibrillation undergoing percutaneous coronary intervention: a jump with a weak parachute?
Eur Heart J Cardiovasc Pharmacother. 2019 Jan 1;5(1):55-56.
86. Uijl A, Lund LH, **Savarese G**.
The GUIDE-IT heart failure risk prediction model: another fish in the sea?
Eur J Heart Fail 2019. doi: 10.1002/ehhf.1472.
87. Faxén UL, Lund LH, Orsini N, Strömberg A, Andersson DC, Linde C, Dahlström U, **Savarese G**
N-terminal pro-B-type natriuretic peptide in chronic heart failure: The impact of sex across the ejection fraction spectrum.
Int J Cardiol. 2019. pii: S0167-5273(19)30390-0. PMID: 31005415
88. **Savarese G***, Chen X*, Dahlström U, Lund LH, Fu M
Age-dependent differences in clinical phenotype and prognosis in heart failure with mid-range ejection compared with heart failure with reduced or preserved ejection fraction.
Clin Res Cardiol. 2019. doi: 10.1007/s00392-019-01477-z. PMID: 30980205
*Equally contribution
89. **Savarese G**, Vedin O, D'Amario D, Uijl A, Dahlstrom U, Rosano G, Lam CSP, Lund LH
Prevalence and prognostic implications of longitudinal ejection fraction change in heart failure
JACC Heart Fail 2019;7:306-317. PMID: 30852236
*Equally contribution
90. **Savarese G**, Sattar N, Januzzi J, Verma S, Lund LH, Fitchett D, Zeller C, George JT, Brueckmann M, Ofstad AP, Inzucchi SE, Wanner C, Zinman B, Butler J.
Empagliflozin Is Associated With a Lower Risk of Postacute Heart Failure Rehospitalization and Mortality. Insights From the EMPA-REG OUTCOME Trial
Circulation 2019;139:1458-1460. PMID: 30855996
91. **Savarese G**, Lund LH, Dahlström U, Strömberg A.
Nurse-Led Heart Failure Clinics Are Associated With Reduced Mortality but Not Heart Failure Hospitalization.
J Am Heart Assoc. 2019 May 21;8(10):e011737
92. Sulzgruber P, Wassmann S, Semb AG, Doehner W, Widimsky P, Gremmel T, Kaski JC, **Savarese G**, Rosano GMC, Borghi C, Kjeldsen K, Torp-Pedersen C, Schmidt TA, Lewis BS, Drexel H, Tamargo J, Atar D, Agewall S, Niessner A.
Oral anticoagulation in patients with non-valvular atrial fibrillation and a CHA2DS2-VASc score of 1: a current opinion of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Council on Stroke.
Eur Heart J Cardiovasc Pharmacother. 2019 Jul 1;5(3):171-180. doi: 10.1093/ehjcvp/pvz016.

93. Kapelios CJ, Lainscak M, **Savarese G**, Laroche C, Seferovic P, Ruschitzka F, Coats A, Anker SD, Crespo-Leiro MG, Filippatos G, Piepoli MF, Rosano G, Zanolla L, Aguiar C, Murin J, Leszek P, McDonagh T, Maggioni AP, Lund LH; HF-LT Registry Investigators Group.
Sacubitril/valsartan eligibility and outcomes in the ESC-EORP-HFA Heart Failure Long-Term Registry: bridging between European Medicines Agency/Food and Drug Administration label, the PARADIGM-HF trial, ESC guidelines, and real world.
Eur J Heart Fail. 2019 May 27. doi: 10.1002/ejhf.1532. [Epub ahead of print]
94. Stolfo D, Uijl A, Vedin O, Strömberg A, Faxén UL, Rosano GMC, Sinagra G, Dahlström U, **Savarese G**.
Sex-Based Differences in Heart Failure Across the Ejection Fraction Spectrum: Phenotyping, and Prognostic and Therapeutic Implications.
JACC Heart Fail. 2019 Jun;7(6):505-515. doi: 10.1016/j.jchf.2019.03.011.
95. **Savarese G**, Lund LH, Carrero JJ.
Reply: Clinical Context of Dyskalemias Across the Heart Failure Spectrum and Their Associated Adverse Outcomes.
JACC Heart Fail. 2019 Jun;7(6):533-534. doi: 10.1016/j.jchf.2019.03.007. No abstract available.
96. Stolfo D, **Savarese G**.
Use of Renin-Angiotensin-Aldosterone System Inhibitors in Older Patients with Heart Failure and Reduced Ejection Fraction.
Card Fail Rev. 2019 May 24;5(2):70-73. doi: 10.15420/cfr.2019.6.2. eCollection 2019 May. Review.
97. Löfström U, Hage C, **Savarese G**, Donal E, Daubert JC, Lund LH, Linde C.
Prognostic impact of Framingham heart failure criteria in heart failure with preserved ejection fraction.
ESC Heart Fail. 2019 Aug;6(4):830-839. doi: 10.1002/ehf2.12458. Epub 2019 Jun 17.
98. Drexel H, Rosano GMC, Lewis BS, Huber K, Vonbank A, Dopheide JF, Mader A, Niessner A, **Savarese G**, Wassmann S, Agewall S.
The age of RCT's 3 Important Aspects of RCT's in Cardiovascular Pharmacotherapy with examples from Lipid and Diabetes Trials.
Eur Heart J Cardiovasc Pharmacother. 2019 Jul 12. pii: pvz029. doi: 10.1093/ehjcvp/pvz029. [Epub ahead of print] No abstract available.
99. **Savarese G**, Reiner MF, Uijl A, D'Amario D, Agewall S, Atar D, Baumgartner I, Borghi C, De Carlo M, Drexel H, Kaski JC, Kjeldsen KP, Kucher N, Lund LH, Niessner A, Semb AG, Schmidt TA, Sulzgruber P, Tamargo J, Vitale C, Wassmann S, Aboyans V, Lewis BS.
Antithrombotic Therapy and Major Adverse Limb Events in Patients With Chronic Lower Extremity Arterial Disease: Systematic Review and Meta-analysis from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy in Collaboration with the European Society of Cardiology Working Group on Aorta & Peripheral Vascular Diseases.
Eur Heart J Cardiovasc Pharmacother. 2019 Aug 8. pii: pvz036. doi: 10.1093/ehjcvp/pvz036. [Epub ahead of print]
100. Hollan I, Ronda N, Dessein P, Agewall S, Karpouzas G, Tamargo J, Niessner A, **Savarese G**, Rosano G, Kaski JC, Wassmann S, Meroni PL.
Lipid management in rheumatoid arthritis: a position paper by the Cardiovascular Pharmacotherapy Working Group of European Society of Cardiology.
Eur Heart J Cardiovasc Pharmacother. 2019 Aug 9. pii: pvz033. doi: 10.1093/ehjcvp/pvz033. [Epub ahead of print]
101. Schrage B, Uijl A, Benson L, Westermann D, Ståhlberg M, Stolfo D, Dahlström U, Linde CM, Braunschweig F, **Savarese G**.

Association Between Use of Primary Prevention Implantable Cardioverter-Defibrillators and Mortality in Patients with Heart Failure: A Prospective Propensity-Score Matched Analysis from the Swedish Heart Failure Registry.

Circulation. 2019 Sep 3. doi: 10.1161/CIRCULATIONAHA.119.043012. [Epub ahead of print]

102. Stolfo D, Uijl A, Benson L, Schrage B, Fudim M, Asselbergs FW, Koudstaal S, Sinagra G, Dahlström U, Rosano G, Savarese G.
Association between beta-blocker use and mortality/morbidity in older patients with heart failure with reduced ejection fraction A propensity score-matched analysis from the Swedish Heart Failure Registry.
Eur J Heart Fail. 2019 Sep 3. doi: 10.1002/ejhf.1615. [Epub ahead of print]
103. Savarese G, Jonsson Å, Hallberg AC, Dahlström U, Edner M, Lund LH.
Prevalence of, associations with, and prognostic role of anemia in heart failure across the ejection fraction spectrum.
Int J Cardiol. 2019 Aug 28. pii: S0167-5273(19)31354-3. doi: 10.1016/j.ijcard.2019.08.049
104. Sulzgruber P, Wassmann S, Semb AG, Doehner W, Widimsky P, Gremmel T, Kaski JC, Savarese G, Rosano GMC, Borghi C, Kjeldsen K, Torp-Pedersen C, Schmidt TA, Lewis BS, Drexel H, Tamargo J, Atar D, Agewall S, Niessner A.
Oral Anticoagulation in patients with non-valvular atrial fibrillation and a CHA2DS2-VASc score of 1.
Eur Heart J. 2019 Sep 21;40(36):3010-3012. doi: 10.1093/eurheartj/ehz650.
105. Savarese G.
Behavioural Interventions to Reduce Cardiovascular Risk: Where Do We Stand?
Eur Cardiol. 2019 Dec 18;14(3):139-140. doi: 10.15420/ecr.2019.
106. Schrage B, Linde C, Braunshweig F, Savarese G
Reply to the letter by Dr. Littmann
Circulation 2020;141:e648-e649.
107. Rossignol P, Lainscak M, Crespo-Leiro MG, Laroche C, Piepoli MF, Filippatos G, Rosano GMC, Savarese G, Anker SD, Seferovic PM, Ruschitzka F, Coats AJS, Mebazaa A, McDonagh T, Sahuquillo A, Penco M, Maggioni AP, Lund LH; Heart Failure Long-Term Registry Investigators Group.
Unravelling the interplay between hyperkalaemia, renin-angiotensin-aldosterone inhibitor use and clinical outcomes. Data from 9222 chronic heart failure patients of the ESC-HFA-EORP Heart Failure Long-Term Registry
Eur J Heart Fail 2020 Apr 3. doi: 10.1002/ejhf.1793. [Epub ahead of print]
108. Lund LH, Savarese G, Dahlström U.
Iron deficiency in heart failure
Int J Cardiol 2020;299:207.
109. Lund LH, Savarese G.
PARAGON-HF - considerations for potential use of sacubitril-valsartan in real-world heart failure with mildly reduced ejection fraction
J Card Fail 2019;25:1012-1013.
110. Stolfo D, Albani S, Savarese G, Barbati G, Ramani F, Gigli M, Biondi F, Dal Ferro M, Zecchin M, Merlo M, Sinagra G.
Risk of sudden cardiac death in New York Heart Association class I patients with dilated cardiomyopathy: A competing risk analysis
Int J Cardiol 2020;307:75-81.

111. Cooper LB, Benson L, Mentz RJ, **Savarese G**, DeVore AD, Carrero JJ, Dahlström U, Anker SD, Lainscak M, Hernandez AF, Pitt B, Lund LH.
Association between potassium level and outcomes in heart failure with reduced ejection fraction: a cohort study from the Swedish Heart Failure Registry
Eur J Heart Fail. 2020. doi: 10.1002/ejhf.1757. [Epub ahead of print]
112. Stolfo D, **Savarese G**.
Sex-related differences in therapeutic response to mineralocorticoid receptor antagonists in heart failure: summarizing trial evidence
Eur J Heart Fail 2020;22:845-847.
113. **Savarese G**, Settergren C, Schrage B, Thorvaldsen T, Löfman I, Sartipy U, Mellbin L, Meyers A, Farsani SF, Brueckmann M, Brodovicz KG, Vedin O, Asselbergs FW, Dahlström U, Cosentino F, Lund LH.
Comorbidities and cause-specific outcomes in heart failure across the ejection fraction spectrum: A blueprint for clinical trial design
Int J Cardiol 2020;313:76-82.
114. Rosano G, **Savarese G**.
Inter-twinned relationship between heart failure and atrial fibrillation
Heart 2020;106:1125-1126.
115. Uijl A, Lund LH, Vaartjes I, Brugts JJ, Linssen GC, Asselbergs FW, Hoes AW, Dahlström U, Koudstaal S, **Savarese G**.
A registry-based algorithm to predict ejection fraction in patients with heart failure
ESC Heart Fail 2020. doi: 10.1002/ehf2.12779.
116. **Savarese G**.
All About Clinical Trial Course: One of the Masterpieces of the European Society of Cardiology - Working Group on Cardiovascular Pharmacotherapy Educational Programme
Eur Heart J Cardiovasc Pharmacother 2020. doi: 10.1093/ehjcvp/pvaa070.
117. Kaski JC, Tamargo J, **Savarese G**.
Cardiovascular Pharmacotherapy in Older People - Challenges Posed by Cardiovascular Drug Prescription in the Elderly
Eur Heart J Cardiovasc Pharmacother 2020. doi: 10.1093/ehjcvp/pvaa090.
118. Schrage B, Lund LH, Benson L, Stolfo D, Ohlsson A, Westerling R, Westermann D, Strömberg A, Dahlström U, Braunschweig F, Ferreira JP, **Savarese G**.
Lower socioeconomic status predicts higher mortality and morbidity in patients with heart failure
Heart 2020 Aug 7; heartjnl-2020-317216.
119. D'Amario D, Camilli M, Migliaro S, Canonico F, Galli M, Arcudi A, Montone RA, Borovac JA, Crea F, **Savarese G**.
Sex-Related Differences in Dilated Cardiomyopathy with a Focus on Cardiac Dysfunction in Oncology
Curr Cardiol Rep 2020;22:102.
120. **Savarese G**, Hage C, Benson L, Schrage B, Thorvaldsen T, Lundberg A, Fudim M, Linde C, Dahlström U, Rosano GM, Lund LH.
Eligibility for sacubitril/valsartan in heart failure across the ejection fraction spectrum: real world data from the Swedish Heart Failure Registry
J Intern Med 2020. doi: 10.1111/joim.13165.
121. Fu EL, Uijl A, Dekker FW, Lund LH, **Savarese G**, Carrero JJ.

Association Between β -Blocker Use and Mortality/Morbidity in Patients With Heart Failure With Reduced, Midrange, and Preserved Ejection Fraction and Advanced Chronic Kidney Disease
Circ Heart Fail 2020. doi: 10.1161/CIRCHEARTFAILURE.120.007180.

122. **Savarese G, Benson L, Sundström J, Lund LH.**
Association between Renin-Angiotensin-Aldosterone system inhibitor use and COVID-19 Hospitalization and death: A 1,4 million patient Nation-Wide registry analysis
Eur J Heart Fail. 2020. doi: 10.1002/ehjhf.2060.
123. **Savarese G.**
New evidence from the scientific sessions 2020 of the American Heart Association
Eur Heart J Cardiovasc Pharmacother 2020. doi: 10.1093/ehjcvp/pvaa143.
124. **Drexel H, Lewis BS, Rosano GMC, Saely CH, Tautermann G, Huber K, Dopheide JF, Kaski JC, Mader A, Niessner A, Savarese G, Schmidt TA, Semb A, Tamargo J, Wassmann S, Kjeldsen KP, Agewall S, Pocock SJ.**
The age of randomized clinical trials: three important aspects of randomized clinical trials in cardiovascular pharmacotherapy with examples from lipid, diabetes, and antithrombotic trials
Eur Heart J Cardiovasc Pharmacother. 2020. doi: 10.1093/ehjcvp/pvaa126.
125. **Saraiva FA, Cerqueira RJ, Savarese G, Leite-Moreira AF.**
The tight tie of MAG versus SAG in CABG
Int J Cardiol. 2020 Oct 7;S0167-5273(20)33919-X. doi: 10.1016/j.ijcard.2020.10.010. PMID: 33038409
126. **Savarese G.**
Latest news on heart failure and atrial fibrillation from the European Society of Cardiology Congress 2020.
Eur Heart J Cardiovasc Pharmacother 2020. doi: 10.1093/ehjcvp/pvaa115.
127. **Savarese G, Cosentino F.**
The interaction between dapagliflozin and blood pressure in heart failure: new evidence dissipating concerns
Eur Heart J. 2020 Sep 21;41(36):3419-3420. doi: 10.1093/eurheartj/ehaa584. PMID: 32901257
128. **Chen X, Savarese G, Cai Y, Ma L, Lundborg CS, Jiang W, Wen Z, Lu W, Marrone G.**
Tai Chi and Qigong Practices for Chronic Heart Failure: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Evid Based Complement Alternat Med. 2020 Dec 14;2020:2034625. doi: 10.1155/2020/2034625. PMID: 33381195
129. **Abraham WT, Lindenfeld J, Ponikowski P, Agostoni P, Butler J, Desai AS, Filippatos G, Gniot J, Fu M, Gullestad L, Howlett JG, Nicholls SJ, Redon J, Schenkenberger I, Silva-Cardoso J, Störk S, Krzysztow Wranicz J, Savarese G, Brueckmann M, Jamal W, Nordaby M, Peil B, Ritter I, Ustyugova A, Zeller C, Salsali A, Anker SD.**
Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes
Eur Heart J. 2021;42:700-710.
130. **Schrage B, Becher PM, Goßling A, Savarese G, Dabboura S, Yan I, Beer B, Söffker G, Seiffert M, Kluge S, Kirchhof P, Blankenberg S, Westermann D.**
Temporal trends in incidence, causes, use of mechanical circulatory support and mortality in cardiogenic shock
ESC Heart Fail 2021. doi: 10.1002/ehf2.13202.

131. Seferović PM, Vardas P, Jankowska EA, Maggioni AP, Timmis A, Milinković I, Polovina M, Gale CP, Lund LH, Lopatin Y, Lainscak M, **Savarese G**, Huculeci R, Kazakiewicz D, Coats AJ; Developed in collaboration with the National Heart Failure Societies of the ESC member countries. The Heart Failure Association Atlas: Heart Failure Epidemiology and Management Statistics 2019 Eur J Heart Fail. 2021. doi: 10.1002/ehf.2143.
132. Uijl A, **Savarese G**, Vaartjes I, Dahlström U, Bruggs JJ, Linssen GCM, van Empel V, Brunner-La Rocca HP, Asselbergs FW, Lund LH, Hoes AW, Koudstaal S.
Identification of distinct phenotypic clusters in heart failure with preserved ejection fraction
Eur J Heart Fail. 2021 Jun;23(6):973-982.
133. Meyer M, Du Fay Lavallaz J, Benson L, **Savarese G**, Dahlström U, Lund LH.
Association Between β -Blockers and Outcomes in Heart Failure With Preserved Ejection Fraction: Current Insights From the SwedeHF Registry
J Card Fail. 2021;S1071-9164(21)00158-5.
134. **Savarese G**, Bodegard J, Norhammar A, Sartipy P, Thuresson M, Cowie MR, Fonarow GC, Vaduganathan M, Coats AJS
Heart failure drug titration, discontinuation, mortality and heart failure hospitalization risk: a multinational observational study (US, UK and Sweden)
Eur J Heart Fail. 2021;23:1499-1511.
135. Schrage B, Beer BN, Savarese G, Dabboura S, Yan I, Sundermeyer J, Becher PM, Grahn H, Seiffert M, Bernhardt A, Thiele H, Möller JE, Kluge S, Reichensperner H, Kirchhof P, Blankenberg S, Westermann D.
Eligibility for mechanical circulatory support devices based on current and past randomised cardiogenic shock trials
Eur J Heart Fail. 2021. doi: 10.1002/ehf.2274.
136. Trevisan M, Fu EL, Xu Y, **Savarese G**, Dekker FW, Lund LH, Clase CM, Sjölander A, Carrero JJ.
Stopping mineralocorticoid receptor antagonists after hyperkalaemia: trial emulation in data from routine care
Eur J Heart Fail. 2021. doi: 10.1002/ehf.2287.
137. **Savarese G**, Uijl A, Lund LH, Anker SD, Asselbergs F, Fitchett D, Inzucchi SE, Koudstaal S, Ofstad AP, Schrage B, Vedin O, Wanner C, Zannad F, Zwiener I, Butler J.
Empagliflozin in Heart Failure With Predicted Preserved Versus Reduced Ejection Fraction: Data From the EMPA-REG OUTCOME Trial
J Card Fail. 2021;27:888-895.
138. Shahim A, Hourqueig M, Donal E, Oger E, Venkateshvaran A, Daubert JC, **Savarese G**, Linde C, Lund LH, Hage C.
Predictors of long-term outcome in heart failure with preserved ejection fraction: a follow-up from the KaRen study.
ESC Heart Fail. 2021. doi: 10.1002/ehf2.13533.
139. Becher PM, Schrage B, Benson L, Fudim M, Corovic Cabrera C, Dahlström U, Rosano GMC, Jankowska EA, Anker SD, Lund LH, **Savarese G**.
Phenotyping heart failure patients for iron deficiency and use of intravenous iron therapy: data from the Swedish Heart Failure Registry.
Eur J Heart Fail. 2021. doi: 10.1002/ehf.2338.
140. Schrage B, Lund LH, Melin M, Benson L, Uijl A, Dahlström U, Braunschweig F, Linde C, **Savarese G**.
Cardiac resynchronization therapy with or without defibrillator in patients with heart failure
Europace. 2021. doi: 10.1093/europace/euab233.

141. Kapelios CJ, Canepa M, Benson L, Hage C, Thorvaldsen T, Dahlström U, Savarese G, Lund LH. **Non-cardiology vs. cardiology care of patients with heart failure and reduced ejection fraction is associated with lower use of guideline-based care and higher mortality: Observations from The Swedish Heart Failure Registry.** Int J Cardiol. 2021:S0167-5273(21)01334-6.
142. Savarese G, Stolfo D, Sinagra G, Lund LH. Heart failure with mid-range or mildly reduced ejection fraction. Nat Rev Cardiol. 2021. doi: 10.1038/s41569-021-00605-5. PMID: 34489589
143. Savarese G, Lund LH, Rosano GMC, Coats AJ. New trial evidence and guidelines on heart failure-news from the European Society of Cardiology Congress 2021 Eur Heart J Cardiovasc Pharmacother. 2021. doi: 10.1093/ehjcvp/pvab071. PMID: 34529057
144. Magavern EF, Kaski JC, Turner RM, Drexel H, Janmohamed A, Scourfield A, Burrage D, Floyd CN, Adeyeye E, Tamargo J, Lewis BS, Kjeldsen KP, Niessner A, Wassmann S, Sulzgruber P, Borry P, Agewall S, Semb AG, Savarese G, Pirmohamed M, Caulfield MJ. Challenges in Cardiovascular Pharmacogenomics Implementation: A viewpoint from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy Eur Heart J Cardiovasc Pharmacother. 2021; doi: 10.1093/ehjcvp/pvab063. PMID: 34463331
145. Becher PM, Savarese G. PharmaPulse: New trial evidence from the HFA/ESC heart failure congress 2021 Eur Heart J Cardiovasc Pharmacother. 2021;pvab066. doi: 10.1093/ehjcvp/pvab066. PMID: 34415014
146. Savarese G, Butler J, Lund LH, Bhatt DL, Anker SD. Cardiovascular effects of non-insulin glucose-lowering agents: a comprehensive review of trial evidence and potential cardioprotective mechanisms Cardiovasc Res. 2021. doi: 10.1093/cvr/cvab271. PMID: 34390570
147. Savarese G, Merlo M, Coats AJS, Metra M. Best of European Journal of Heart Failure at the ESC/HFA Heart Failure Congress 2021 Eur J Heart Fail. 2021 Sep;23(9):1424-1427. PMID: 34263508
148. Herrington WG, Savarese G, Haynes R, Marx N, Mellbin L, Lund LH, Dendale P, Seferovic P, Rosano G, Staplin N, Baigent C, Cosentino F. Cardiac, renal, and metabolic effects of sodium-glucose co-transporter 2 inhibitors: a position paper from the European Society of Cardiology ad-hoc task force on sodium-glucose co-transporter 2 inhibitors Eur J Heart Fail. 2021;23:1260-1275. PMID: 34184823
149. Drexel H, Pocock SJ, Lewis BS, Saely CH, Kaski JC, Rosano GMC, Tautermann G, Huber K, Doppeide JF, Mader A, Niessner A, Savarese G, Schmidt TA, Semb AG, Tamargo J, Wassmann S, Clodi M, Kjeldsen KP, Agewall S. Subgroup analyses in randomized clinical trials: Value and limitations Review #3 on important aspects of randomized clinical trials in cardiovascular pharmacotherapy Eur Heart J Cardiovasc Pharmacother. 2021. doi: 10.1093/ehjcvp/pvab048. PMID: 34180504
150. Stolfo D, Savarese G. Association between heart failure and cancer: is gender the answer? Eur J Heart Fail. 2021 Jun 11. doi: 10.1002/ehjhf.2261. PMID: 34114282
151. Sinagra G, Pagura L, Stolfo D, Fabris E, Savarese G, Rapezzi C, Ferrari R, Merlo M. Combining New Classes of Drugs for HFrEF: from Trials to Clinical Practice Eur J Intern Med. 2021 Aug;90:10-15. PMID: 34090751

152. Kapelios CJ, Canepa M, Savarese G, Lund LH.
Use of loop diuretics in chronic heart failure: do we adhere to the Hippocratic principle 'do no harm'?
Eur J Heart Fail. 2021;23:1068-1075. PMID: 33963796
153. Krogager ML, Kragholm K, Thomassen JQ, Søgaard P, Lewis BS, Wassmann S, Baumgartner I, Ceconi C, Schmidt TA, Kaski JC, Drexel H, Semb AG, Agewall S, Niessner A, Savarese G, Kjeldsen KP, Borghi C, Tamargo J, Torp-Pedersen C.
Update on management of hypokalemia and goals for the lower potassium level in patients with cardiovascular disease: A review in collaboration with the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy
Eur Heart J Cardiovasc Pharmacother. 2021. doi: 10.1093/ehjcvp/pvab038. PMID: 33956964
154. Rao VN, Fudim M, Savarese G, Butler J.
Polypharmacy in Heart Failure with Reduced Ejection Fraction: Progress, Not Problem
Am J Med. 2021;134:1068-1070. PMID: 33939999
155. Rosano GMC, Moura B, Metra M, Böhm M, Bauersachs J, Ben Gal T, Adamopoulos S, Abdelhamid M, Bistola V, Čelutkienė J, Chioncel O, Farmakis D, Ferrari R, Filippatos G, Hill L, Jankowska EA, Jaarsma T, Jhund P, Lainscak M, Lopatin Y, Lund LH, Milicic D, Mullens W, Pinto F, Ponikowski P, Savarese G, Thum T, Volterrani M, Anker SD, Seferovic PM, Coats AJS.
Patient profiling in heart failure for tailoring medical therapy. A consensus document of the Heart Failure Association of the European Society of Cardiology
Eur J Heart Fail. 2021;23:872-881. PMID: 33932268
156. Ferrannini G, Savarese G, Rydén L.
Sodium-glucose transporter inhibition in heart failure: from an unexpected side effect to a novel treatment possibility
Diabetes Res Clin Pract. 2021;175:108796. PMID: 33845051
157. Magavern EF, Kaski JC, Turner RM, Drexel H, Janmohamed A, Scourfield A, Burrage D, Floyd CN, Adeyeye E, Tamargo J, Lewis BS, Kjeldsen KP, Niessner A, Wassmann S, Sulzgruber P, Borry P, Agewall S, Semb AG, Savarese G, Pirmohamed M, Caulfield MJ.
The Role of Pharmacogenomics in Contemporary Cardiovascular Therapy: A position statement from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy
Eur Heart J Cardiovasc Pharmacother. 2021. doi: 10.1093/ehjcvp/pvab018.
158. Rosano G, Vitale C, Savarese G.
Sodium-Glucose Co-transporter 2 Inhibitors in Heart Failure.
Eur Heart J Cardiovasc Pharmacother 2021. doi: 10.1093/ehjcvp/pvab012. PMID: 33576409
159. Khan Minhas AM, Salah HM, Khan MS, Rao VN, Tedford RJ, ReddyMD YNV, Caughey MC, Savarese G, Greene SJ, Michos ED, Fudim M.
Most Common Causes of Hospitalization Associated with Inpatient Mortality in the United States between 2005-2018.
Am J Med Sci. 2022. doi: 10.1016/j.amjms.2022.01.009. PMID: 35090870
160. Kapłan-Cieślicka A, Benson L, Chioncel O, Crespo-Leiro MG, Coats AJS, Anker SD, Filippatos G, Ruschitzka F, Hage C, Drożdż J, Seferovic P, Rosano GMC, Piepoli M, Mebazaa A, McDonagh T, Lainscak M, Savarese G, Ferrari R, Maggioni AP, Lund LH; on behalf of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC) and the ESC Heart Failure Long-Term Registry Investigators.
A comprehensive characterization of acute heart failure with preserved versus mildly reduced versus reduced ejection fraction - insights from the ESC-HFA EORP Heart Failure Long-Term Registry.
Eur J Heart Fail. 2021 Dec 27. doi: 10.1002/ehhf.2408. PMID: 34962044

161. Kapelios CJ, Lund LH, Benson L, Dahlström U, Rosano GMC, Hauptman PJ, **Savarese G**.
Digoxin use in contemporary heart failure with reduced ejection fraction: an analysis from the Swedish Heart Failure Registry.
Eur Heart J Cardiovasc Pharmacother. 2021. doi: 10.1093/ehjcvp/pvab079. PMID: 34921603
162. Lund LH, **Savarese G**, Venkateshvaran A, Benson L, Lundberg A, Donal E, Daubert JC, Oger E, Linde C, Hage C.
Eligibility of patients with heart failure with preserved ejection fraction for sacubitril/valsartan according to the PARAGON-HF trial.
ESC Heart Fail. 2022;9:164-177. doi: 10.1002/ehf2.13705. PMID: 34811954
163. Fudim M, Devaraj S, Chukwurah M, Ajam T, Razaghizad A, Salah HM, Sharma A, **Savarese G**, Vaduganathan M, Kamalesh M.
Prognosis for patients with heart failure and reduced ejection fraction with and without diabetes: A 7 year nationwide veteran administration analysis.
Int J Cardiol. 2022;346:30-34. doi: 10.1016/j.ijcard.2021.11.032. PMID: 34800593
164. Lim YMF, Molnar M, Vaartjes I, **Savarese G**, Eijkemans MJC, Uijl A, Vradi E, Suzart-Woischnik K, Brugts JJ, Brunner-La Rocca HP, Blanc-Guillemaud V, Couvelard F, Baudier C, Dyszynski T, Waechter S, Lund LH, Hoes AW, Tyl B, Asselbergs FW, Gerlinger C, Grobbee DE, Cronin M, Koudstaal S
Generalisability of Randomised Controlled Trials in Heart Failure with Reduced Ejection Fraction.
Eur Heart J Qual Care Clin Outcomes. 2021. doi: 10.1093/ehjqcco/qcab070. PMID: 34596659
165. **Savarese G**, Lund LH, Rosano GMC, Coats AJ.
New trial evidence and guidelines on heart failure: news from the European Society of Cardiology Congress 2021.
Eur Heart J Cardiovasc Pharmacother. 2021;7:e89-e90. doi: 10.1093/ehjcvp/pvab071. PMID: 34529057.
166. Rosano G, Jankowska EA, Ray R, Metra M, Abdelhamid M, Adamopoulos S, Anker SD, Bayes-Genis A, Belenkov Y, Gal TB, Böhm M, Chioncel O, Cohen-Solal A, Farmakis D, Filippatos G, González A, Gustafsson F, Hill L, Jaarsma T, Jouhra F, Lainscak M, Lambrinou E, Lopatin Y, Lund LH, Milicic D, Moura B, Mullens W, Piepoli MF, Ponikowski P, Rakisheva A, Ristic A, **Savarese G**, Seferovic P, Senni M, Thum T, Tocchetti CG, Van Linthout S, Volterrani M, Coats AJS.
COVID-19 vaccination in patients with heart failure: a position paper of the Heart Failure Association of the European Society of Cardiology.
Eur J Heart Fail. 2021 Nov;23(11):1806-1818. doi: 10.1002/ejhf.2356. PMID: 34612556
167. Rosano GMC, Allen LA, Abdin A, Lindenfeld J, O'Meara E, Lam CSP, Lancellotti P, **Savarese G**, Gottlieb SS, Teerlink J, Wintrich J, Böhm M
Drug Layering in Heart Failure: Phenotype-Guided Initiation.
JACC Heart Fail. 2021 Nov;9(11):775-783. doi: 10.1016/j.jchf.2021.06.011.
168. Uijl A, Lund LH, Asselbergs FW, **Savarese G**
Methodological issues in meta-analyses of real-world clinical data to infer causality.
Int J Cardiol. 2021;345:107-108. doi: 10.1016/j.ijcard.2021.10.029. PMID: 34688720
169. Lund LH, Hage C, **Savarese G**.
Implementation science and potential for screening in heart failure.
Eur Heart J. 2021. doi: 10.1093/eurheartj/ehab751. PMID: 34751776
170. Mullens W, Coats A, Seferovic P, Metra M, Mebazaa A, Ruschitzka F, Filippatos G, Volterrani M, Ponikowski P, Jankowska EA, Chioncel O, McDonagh TA, Piepoli MF, Milicic D, Thum T, Hill L, Abdelhamid M, Adamopoulos S, Belenkov Y, Gal TB, Böhm M, Cohen-Solal A, Gustafsson F, Jaarsma T, Moura B, Rakisheva A, Ristic A, Bayes-Genis A, Van Linthout S, Anker SD, Tocchetti CG, Lopatin Y,

Lund L, Savarese G, Čelutkienė J, Cowie M, Lambrinou E, Ray R, Lainscak M, Skouri H, Wallner M, Rosano GMC

Education and certification on heart failure of the Heart Failure Association of the European Society of Cardiology.

Eur J Heart Fail. 2022. doi: 10.1002/ehhf.2430. PMID: 35014132

171. Palazzuoli A, Savarese G
An update on diabetes spectrum in heart failure: current evidence and potential therapeutic applications.
Heart Fail Rev. 2022. doi: 10.1007/s10741-021-10202-w. PMID: 35067834
172. Minhas AMK, Salah HM, Khan MS, Rao VN, Tedford RJ, Reddy YNV, Caughey MC, Savarese G, Greene SJ, Michos ED, Fudim M.
Most Common Causes of Hospitalization Associated with Inpatient Mortality in the United States Between 2005-2018.
Am J Med Sci. 2022 May;363(5):459-461. doi: 10.1016/j.amjms.2022.01.009. Epub 2022 Jan 26.
173. Tamargo J, Kjeldsen KP, Delpón E, Semb AG, Cerbai E, Dobrev D, Savarese G, Sulzgruber P, Rosano G, Borghi C, Wassman S, Torp-Pedersen CT, Agewall S, Drexel H, Baumgartner I, Lewis B, Ceconi C, Kaski JC, Niessner A.
Facing the challenge of polypharmacy when prescribing for older people with cardiovascular disease. A review by the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy.
Eur Heart J Cardiovasc Pharmacother. 2022 Jun 8;8(4):406-419. doi: 10.1093/ehjcvp/pvac005.
174. Savarese G, Becher PM, Lund LH, Seferovic P, Rosano GMC, Coats AJS.
Global burden of heart failure: a comprehensive and updated review of epidemiology.
Cardiovasc Res. 2023 Jan 18;118(17):3272-3287. doi: 10.1093/cvr/cvac013.
175. Albani S, Stolfo D, Venkateshvaran A, Chubuchny V, Biondi F, De Luca A, Lo Giudice F, Pasanisi EM, Petersen C, Airò E, Bauleo C, Ciardetti M, Coceani M, Formichi B, Spiesshoefer J, Savarese G, Lund LH, Emdin M, Sinagra G, Manouras A, Giannoni A; European Echo-Net Working Group.
Echocardiographic Biventricular Coupling Index to Predict Precapillary Pulmonary Hypertension.
J Am Soc Echocardiogr. 2022 Jul;35(7):715-726. doi: 10.1016/j.echo.2022.02.003. Epub 2022 Feb 11.
176. Lindberg F, Lund LH, Benson L, Schrage B, Edner M, Dahlström U, Linde C, Rosano G, Savarese G.
Patient profile and outcomes associated with follow-up in specialty vs. primary care in heart failure.
ESC Heart Fail. 2022 Apr;9(2):822-833. doi: 10.1002/ehf2.13848. Epub 2022 Feb 15.
177. D'Amario D, Rodolico D, Rosano GMC, Dahlström U, Crea F, Lund LH, Savarese G.
Association between dosing and combination use of medications and outcomes in heart failure with reduced ejection fraction: data from the Swedish Heart Failure Registry.
Eur J Heart Fail. 2022 May;24(5):871-884. doi: 10.1002/ehhf.2477. Epub 2022 Mar 23.
178. Stolfo D, Lund LH, Becher PM, Orsini N, Thorvaldsen T, Benson L, Hage C, Dahlström U, Sinagra G, Savarese G.
Use of evidence-based therapy in heart failure with reduced ejection fraction across age strata.
Eur J Heart Fail. 2022 Jun;24(6):1047-1062. doi: 10.1002/ehhf.2483. Epub 2022 Apr 3.
179. De Marzo V, Savarese G, Tricarico L, Hassan S, Iacoviello M, Porto I, Ameri P.
Network meta-analysis of medical therapy efficacy in more than 90,000 patients with heart failure and reduced ejection fraction.
J Intern Med. 2022 Aug;292(2):333-349. doi: 10.1111/joim.13487. Epub 2022 Apr 12.

180. González A, Richards AM, de Boer RA, Thum T, Arfsten H, Hülsmann M, Falcao-Pires I, Díez J, Foo RSY, Chan MY, Aimo A, Anene-Nzeli CG, Abdelhamid M, Adamopoulos S, Anker SD, Belenkov Y, Ben Gal T, Cohen-Solal A, Böhm M, Chioncel O, Delgado V, Emdin M, Jankowska EA, Gustafsson F, Hill L, Jaarsma T, Januzzi JL, Jhund PS, Lopatin Y, Lund LH, Metra M, Milicic D, Moura B, Mueller C, Mullens W, Núñez J, Piepoli MF, Rakisheva A, Ristić AD, Rossignol P, **Savarese G**, Tocchetti CG, Van Linthout S, Volterrani M, Seferovic P, Rosano G, Coats AJS, Bayés-Genís A.
Cardiac remodelling - Part 1: From cells and tissues to circulating biomarkers. A review from the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology.
Eur J Heart Fail. 2022 Jun;24(6):927-943. doi: 10.1002/ejhf.2493. Epub 2022 Apr 21.
181. **Savarese G**, Uijl A, Ouwerkerk W, Tromp J, Anker SD, Dickstein K, Hage C, Lam CSP, Lang CC, Metra M, Ng LL, Orsini N, Samani NJ, van Veldhuisen DJ, Cleland JGF, Voors AA, Lund LH.
Biomarker changes as surrogate endpoints in early-phase trials in heart failure with reduced ejection fraction.
ESC Heart Fail. 2022 Aug;9(4):2107-2118. doi: 10.1002/ehf2.13917. Epub 2022 Apr 6.
182. Manca P, Stolfo D, Merlo M, Gregorio C, Cannatà A, Ramani F, Nuzzi V, Lund LH, **Savarese G**, Sinagra G.
Transient versus persistent improved ejection fraction in non-ischaemic dilated cardiomyopathy.
Eur J Heart Fail. 2022 Jul;24(7):1171-1179. doi: 10.1002/ejhf.2512. Epub 2022 May 9.
183. Aimo A, Vergaro G, González A, Barison A, Lupón J, Delgado V, Richards AM, de Boer RA, Thum T, Arfsten H, Hülsmann M, Falcao-Pires I, Díez J, Foo RSY, Chan MYY, Anene-Nzeli CG, Abdelhamid M, Adamopoulos S, Anker SD, Belenkov Y, Ben Gal T, Cohen-Solal A, Böhm M, Chioncel O, Jankowska EA, Gustafsson F, Hill L, Jaarsma T, Januzzi JL, Jhund P, Lopatin Y, Lund LH, Metra M, Milicic D, Moura B, Mueller C, Mullens W, Núñez J, Piepoli MF, Rakisheva A, Ristić AD, Rossignol P, **Savarese G**, Tocchetti CG, van Linthout S, Volterrani M, Seferovic P, Rosano G, Coats AJS, Emdin M, Bayes-Genis A.
Cardiac remodelling - Part 2: Clinical, imaging and laboratory findings. A review from the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology.
Eur J Heart Fail. 2022 Jun;24(6):944-958. doi: 10.1002/ejhf.2522. Epub 2022 May 16.
184. Schrage B, Lund LH, Benson L, Dahlström U, Shadman R, Linde C, Braunschweig F, Levy WC, **Savarese G**.
Predictors of primary prevention implantable cardioverter-defibrillator use in heart failure with reduced ejection fraction: impact of the predicted risk of sudden cardiac death and all-cause mortality.
Eur J Heart Fail. 2022 Jul;24(7):1212-1222. doi: 10.1002/ejhf.2530. Epub 2022 May 22.
185. Stolfo D, Sinagra G, **Savarese G**.
Evidence-based Therapy in Older Patients with Heart Failure with Reduced Ejection Fraction.
Card Fail Rev. 2022 Apr 28;8:e16. doi: 10.15420/cfr.2021.34. eCollection 2022 Jan.
186. Thorvaldsen T, Ferrannini G, Mellbin L, Benson L, Cosentino F, McMurray JJV, Dahlström U, Lund LH, **Savarese G**.
Eligibility for Dapagliflozin and Empagliflozin in a Real-world Heart Failure Population.
J Card Fail. 2022 Jul;28(7):1050-1062. doi: 10.1016/j.cardfail.2022.04.011. Epub 2022 May 10.
187. Becher PM, Lund LH, Coats AJS, **Savarese G**.
An update on global epidemiology in heart failure.
Eur Heart J. 2022 Aug 21;43(32):3005-3007. doi: 10.1093/eurheartj/ehac248.
188. Ferrannini G, **Savarese G**.
New Trial Evidence on Heart Failure: Highlights from the European Society of Cardiology Congress 2021.
Eur Cardiol. 2022 May 13;17:e12. doi: 10.15420/ecr.2022.06. eCollection 2022 Feb.

189. Jackson AM, Benson L, **Savarese G**, Hage C, Jhund PS, Petrie MC, Dahlström U, McMurray JJV, Lund LH.
Apparent Treatment-Resistant Hypertension Across the Spectrum of Heart Failure Phenotypes in the Swedish HF Registry.
JACC Heart Fail. 2022 Jun;10(6):380-392. doi: 10.1016/j.jchf.2022.04.006.
190. Abdelhamid M, Rosano G, Metra M, Adamopoulos S, Böhm M, Chioncel O, Filippatos G, Jankowska EA, Lopatin Y, Lund L, Milicic D, Moura B, Ben Gal T, Ristic A, Rakisheva A, **Savarese G**, Mullens W, Piepoli M, Bayes-Genis A, Thum T, Anker SD, Seferovic P, Coats AJS.
Prevention of sudden death in heart failure with reduced ejection fraction: do we still need an implantable cardioverter-defibrillator for primary prevention?
Eur J Heart Fail. 2022 Sep;24(9):1460-1466. doi: 10.1002/ejhf.2594. Epub 2022 Jul 16.
191. Stolfo D, Fabris E, Lund LH, **Savarese G**, Sinagra G.
From mid-range to mildly reduced ejection fraction heart failure: A call to treat.
Eur J Intern Med. 2022 Sep;103:29-35. doi: 10.1016/j.ejim.2022.05.030. Epub 2022 Jun 14.
192. von Olshausen G, Benson L, Dahlström U, Lund LH, **Savarese G**, Braunschweig F.
Catheter ablation for patients with atrial fibrillation and heart failure: insights from the Swedish Heart Failure Registry.
Eur J Heart Fail. 2022 Sep;24(9):1636-1646. doi: 10.1002/ejhf.2604. Epub 2022 Jul 20.
193. Butler J, Shahzeb Khan M, Lindenfeld J, Abraham WT, **Savarese G**, Salsali A, Zeller C, Peil B, Filippatos G, Ponikowski P, Anker SD.
Minimally Clinically Important Difference in Health Status Scores in Patients With HFrEF vs HFpEF.
JACC Heart Fail. 2022 Sep;10(9):651-661. doi: 10.1016/j.jchf.2022.03.003. Epub 2022 Jun 8.
194. Janse RJ, Fu EL, Dahlström U, Benson L, Lindholm B, van Diepen M, Dekker FW, Lund LH, Carrero JJ, **Savarese G**.
Use of guideline-recommended medical therapy in patients with heart failure and chronic kidney disease: from physician's prescriptions to patient's dispensations, medication adherence and persistence.
Eur J Heart Fail. 2022 Nov;24(11):2185-2195. doi: 10.1002/ejhf.2620. Epub 2022 Aug 2.
195. Rosano GMC, Seferovic P, **Savarese G**, Spoletini I, Lopatin Y, Gustafsson F, Bayes-Genis A, Jaarsma T, Abdelhamid M, Miqueo AG, Piepoli M, Tocchetti CG, Ristić AD, Jankowska E, Moura B, Hill L, Filippatos G, Metra M, Milicic D, Thum T, Chioncel O, Ben Gal T, Lund LH, Farmakis D, Mullens W, Adamopoulos S, Böhm M, Norhammar A, Bollmann A, Banerjee A, Maggioni AP, Voors A, Solal AC, Coats AJS.
Impact analysis of heart failure across European countries: an ESC-HFA position paper.
ESC Heart Fail. 2022 Oct;9(5):2767-2778. doi: 10.1002/ehf2.14076. Epub 2022 Jul 22.
196. Bäck M, Banach M, Braunschweig F, De Rosa S, Gimelli A, Kahan T, Ketelhuth DFJ, Lancellotti P, Larsson SC, Mellbin L, Nagy E, **Savarese G**, Szummer K, Wahl D; European Heart Journal Open Section Editors.
Open Up your Science in EHJ Open.
Eur Heart J Open. 2021 Aug 27;1(1):oeab021. doi: 10.1093/ehjopen/oeab021. eCollection 2021 Aug.
197. Canepa M, Kapelios CJ, Benson L, **Savarese G**, Lund LH.
Temporal Trends of Heart Failure Hospitalizations in Cardiology Versus Noncardiology Wards According to Ejection Fraction: 16-Year Data From the SwedeHF Registry.
Circ Heart Fail. 2022 Aug;15(8):e009462. doi: 10.1161/CIRCHEARTFAILURE.121.009462. Epub 2022

198. Ferrannini G, Lund LH, Benson L, Rizzo M, Almahmeed W, Rosano GMC, **Savarese G**, Cosentino F. **Association between use of novel glucose-lowering drugs and COVID-19 hospitalization and death in patients with type 2 diabetes: a nationwide registry analysis.** Eur Heart J Cardiovasc Pharmacother. 2022 Dec 15;9(1):10-17. doi: 10.1093/ehjcvp/pvac044.
199. Lindberg F, Lund LH, Benson L, Dahlström U, Karlström P, Linde C, Rosano G, **Savarese G**. **Trajectories in New York Heart Association functional class in heart failure across the ejection fraction spectrum: data from the Swedish Heart Failure Registry.** Eur J Heart Fail. 2022 Nov;24(11):2093-2104. doi: 10.1002/ejhf.2644. Epub 2022 Aug 23.
200. Lyon AR, López-Fernández T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, Boriani G, Cardinale D, Cordoba R, Cosyns B, Cutter DJ, de Azambuja E, de Boer RA, Dent SF, Farmakis D, Gevaert SA, Gorog DA, Herrmann J, Lenihan D, Moslehi J, Moura B, Salinger SS, Stephens R, Suter TM, Szmit S, Tamargo J, Thavendiranathan P, Tocchetti CG, van der Meer P, van der Pal HJH; ESC Scientific Document Group. **2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS).** Eur Heart J. 2022 Nov 1;43(41):4229-4361. doi: 10.1093/eurheartj/ehac244.
201. Lyon AR, López-Fernández T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, Boriani G, Cardinale D, Cordoba R, Cosyns B, Cutter DJ, de Azambuja E, de Boer RA, Dent SF, Farmakis D, Gevaert SA, Gorog DA, Herrmann J, Lenihan D, Moslehi J, Moura B, Salinger SS, Stephens R, Suter TM, Szmit S, Tamargo J, Thavendiranathan P, Tocchetti CG, van der Meer P, van der Pal HJH; ESC Scientific Document Group. **2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS).** Eur Heart J Cardiovasc Imaging. 2022 Sep 10;23(10):e333-e465. doi: 10.1093/ehjci/jeac106.
202. Working Group of the Heart Failure Association, European Society of Cardiology. Núñez J, de la Espriella R, Rossignol P, Voors AA, Mullens W, Metra M, Chioncel O, Januzzi JL, Mueller C, Richards AM, de Boer RA, Thum T, Arfsten H, González A, Abdelhamid M, Adamopoulos S, Anker SD, Gal TB, Biegus J, Cohen-Solal A, Böhm M, Emdin M, Jankowska EA, Gustafsson F, Hill L, Jaarsma T, Jhund PS, Lopatin Y, Lund LH, Milicic D, Moura B, Piepoli MF, Ponikowski P, Rakisheva A, Ristic A, **Savarese G**, Tocchetti CG, Van Linthout S, Volterrani M, Seferovic P, Rosano G, Coats AJS, Bayes-Genis A. **Congestion in heart failure: a circulating biomarker-based perspective. A review from the Biomarkers** Eur J Heart Fail. 2022 Oct;24(10):1751-1766. doi: 10.1002/ejhf.2664. Epub 2022 Sep 7.
203. Zito A, Princi G, Romiti GF, Galli M, Basili S, Liuzzo G, Sanna T, Restivo A, Ciliberti G, Trani C, Burzotta F, Cesario A, **Savarese G**, Crea F, D'Amario D. **Device-based remote monitoring strategies for congestion-guided management of patients with heart failure: a systematic review and meta-analysis.** Eur J Heart Fail. 2022 Dec;24(12):2333-2341. doi: 10.1002/ejhf.2655. Epub 2022 Sep 11.
204. **Savarese G**, Sharma A, Pang C, Wood R, Soleymanlou N. **Patient preferences for newer oral therapies in type 2 diabetes.** Int J Cardiol. 2023 Jan 15;371:526-532. doi: 10.1016/j.ijcard.2022.09.009. Epub 2022 Sep 10.
205. Ferrannini G, **Savarese G**, Cosentino F. **SGLT2 Inhibitors in Type 2 Diabetes Mellitus.** Heart Fail Clin. 2022 Oct;18(4):551-559. doi: 10.1016/j.hfc.2022.03.009.

206. **Savarese G**, Kishi T, Vardeny O, Adamsson Eryd S, Bodegård J, Lund LH, Thuresson M, Bozkurt B. **Heart Failure Drug Treatment-Inertia, Titration, and Discontinuation: A Multinational Observational Study (EVOLUTION HF).**
JACC Heart Fail. 2023 Jan;11(1):1-14. doi: 10.1016/j.jchf.2022.08.009. Epub 2022 Sep 7.
207. **Savarese G**, von Haehling S, Butler J, Cleland JGF, Ponikowski P, Anker SD. **Iron deficiency and cardiovascular disease.**
Eur Heart J. 2023 Jan 1;44(1):14-27. doi: 10.1093/eurheartj/ehac569.
208. Ahlgrim C, Kocher S, Minners J, Jander N, **Savarese G**, Neumann FJ, Arentz T, Jadidi A, Mueller-Edenborn B. **Pulmonary Capillary Wedge Pressure during Exercise Is Prognostic for Long-Term Survival in Patients with Symptomatic Heart Failure.**
J Clin Med. 2022 Oct 6;11(19):5901. doi: 10.3390/jcm11195901.
209. Stolfo D, Lund LH, Benson L, Hage C, Sinagra G, Dahlström U, **Savarese G**. **Persistent High Burden of Heart Failure Across the Ejection Fraction Spectrum in a Nationwide Setting.**
J Am Heart Assoc. 2022 Nov 15;11(22):e026708. doi: 10.1161/JAHA.122.026708. Epub 2022 Nov 3.
210. Kaski JC, Semb AG, **Savarese G**. **Advancing medical education-a brief report by the ESC Working Group on Cardiovascular Pharmacotherapy.**
Eur Heart J Cardiovasc Pharmacother. 2022 Dec 15;9(1):6-7. doi: 10.1093/ehjcvp/pvac057.
211. Batra G, Aktaa S, Benson L, Dahlström U, Hage C, **Savarese G**, Vasko P, Gale CP, Lund LH. **Association between heart failure quality of care and mortality: a population-based cohort study using nationwide registries.**
Eur J Heart Fail. 2022 Nov;24(11):2066-2077. doi: 10.1002/ejhf.2725. Epub 2022 Nov 9.
212. **Savarese G**, Lindenfeld J, Stolfo D, Adams K, Ahmad T, Desai NR, Ammirati E, Gottlieb SS, Psotka MA, Rosano GMC, Allen LA. **Use of patient-reported outcomes in heart failure: from clinical trials to routine practice.**
Eur J Heart Fail. 2023 Feb;25(2):139-151. doi: 10.1002/ejhf.2778. Epub 2023 Jan 30.
213. Bäck M, Banach M, Braunschweig F, De Rosa S, Gimelli A, Kahan T, Ketelhuth DFJ, Lancellotti P, Larsson SC, Mellbin L, Nagy E, **Savarese G**, Szummer K, Wahl D; European Heart Journal Open Section Editors. **Highlights from 2022 in EHJ Open.**
Eur Heart J Open. 2022 Dec 30;2(6):oeac084. doi: 10.1093/ehjopen/oeac084. eCollection 2022 Nov.
214. Cappannoli L, Galli M, Zito A, Restivo A, Princi G, Laborante R, Vergallo R, Romagnoli E, Leone AM, Aurigemma C, Massetti M, Sanna T, Trani C, Burzotta F, **Savarese G**, Crea F, D'Amario D. **Venoarterial extracorporeal membrane oxygenation (VA-ECMO) with vs without left ventricular unloading by Impella: a systematic review and meta-analysis.**
Eur Heart J Qual Care Clin Outcomes. 2022 Nov 12:qcac076. doi: 10.1093/ehjqcco/qcac076. Online ahead of print.
215. Becher PM, **Savarese G**, Benson L, Dahlström U, Karlström P, Mol PGM, Metra M, Bhatt DL, Pitt B, Lund LH. **Eligibility for sotagliflozin in a real-world heart failure population based on the SOLOIST-WHF trial enrolment criteria: Data from the swedish heart failure registry.**
Eur Heart J Cardiovasc Pharmacother. 2023 Jan 30:pvad012. doi: 10.1093/ehjcvp/pvad012. Online ahead of print.

216. Hage C, Savarese G.
Proteomic profiling for investigating the pathophysiology of myocardial infarction.
Eur J Prev Cardiol. 2023 Jan 26;zwad019. doi: 10.1093/eurjpc/zwad019. Online ahead of print.
217. Sardu C, Santulli G, Savarese G, Trotta MC, Sacra C, Santamaria M, Volpicelli M, Ruocco A, Mauro C, Signoriello G, Marfella L, D'Amico M, Marfella R, Paolisso G.
Endothelial Dysfunction Drives CRTd Outcome at 1-Year Follow-Up: A Novel Role as Biomarker for miR-130a-5p.
Int J Mol Sci. 2023 Jan 12;24(2):1510. doi: 10.3390/ijms24021510.
218. Kapelios CJ, Benson L, Crespo-Leiro MG, Anker SD, Coats AJS, Chioncel O, Filippatos G, Lainscak M, McDonagh T, Mebazaa A, Metra M, Piepoli MF, Rosano GMC, Ruschitzka F, Savarese G, Seferovic PM, Volterrani M, Maggioni AP, Lund LH.
Participation in a clinical trial is associated with lower mortality but not lower risk of HF hospitalization in patients with heart failure: observations from the ESC EORP Heart Failure Long-Term Registry.
Eur Heart J. 2023 Mar 4;ehad109. doi: 10.1093/eurheartj/ehad109. Online ahead of print.
219. Cappelletto C, Stolfo D, Orsini N, Benson L, Rodolico D, Rosano GMC, Dahlström U, Sinagra G, Lund LH, Savarese G.
Use of and association between heart failure pharmacological treatments and outcomes in obese versus non-obese patients with heart failure with reduced ejection fraction: data from the Swedish Heart Failure Registry.
Eur J Heart Fail. 2023 Feb 13. doi: 10.1002/ehf.2795. Online ahead of print.
220. Faxén J, Benson L, Mantel Å, Savarese G, Hage C, Dahlström U, Askling J, Lund LH, Andersson DC.
Associations between rheumatoid arthritis, incident heart failure, and left ventricular ejection fraction.
Am Heart J. 2023 Feb 10;259:42-51. doi: 10.1016/j.ahj.2023.02.001. Online ahead of print.
221. Rosano GMC, Savarese G.
Implementing an earlier and more intensive follow-up in acute heart failure: the STRONG-HF and COACH trials.
Nat Rev Cardiol. 2023 Apr;20(4):213-214. doi: 10.1038/s41569-023-00841-x.
222. Salah HM, Savarese G, Rosano GMC, Ambrosy AP, Mentz RJ, Fudim M.
Intravenous iron infusion in patients with heart failure: a systematic review and study-level meta-analysis.
ESC Heart Fail. 2023 Feb 2. doi: 10.1002/ehf2.14310. Online ahead of print.
223. Burger PM, Koudstaal S, Dorresteyn JAN, Savarese G, van der Meer MG, de Borst GJ, Mosterd A, Visseren FLJ; UCC-SMART study group.
Metabolic syndrome and risk of incident heart failure in non-diabetic patients with established cardiovascular disease.
Int J Cardiol. 2023 Mar 11:S0167-5273(23)00395-9. doi: 10.1016/j.ijcard.2023.03.024. Online ahead of print.
224. Shahim A, Hourqueig M, Lund LH, Savarese G, Oger E, Venkateshvaran A, Benson L, Daubert JC, Linde C, Donal E, Hage C.
Long-term outcomes in heart failure with preserved ejection fraction: Predictors of cardiac and non-cardiac mortality.
ESC Heart Fail. 2023 Mar 10. doi: 10.1002/ehf2.14302. Online ahead of print.

LIST OF GENERAL ARTICLES AND BOOK CHAPTERS

1. Title Chapter: Definition, epidemiology and burden of disease – HFpEF.

Authors: Lund LH and **Savarese G**

Book Title: The ESC Textbook of Cardiovascular Medicine – Third Edition

Editors: Luscher TF, Camm AJ, Serruys P, Maurer G

Publisher: Oxford Medicine

2. Title Chapter: Sex differences in heart failure

Authors: **Savarese G** and D'Amario D

Book Title: Sex-specific analysis of cardiovascular function

Editors: Kerkhof P and Miller V

Publisher: Springer 2018

3. Title Chapter: Liver and gut dysfunction

Authors: Lopatin Y and **Savarese G**

Book Title: HFA textbook of Heart Failure (in press) – Textbook on heart failure produced by the Heart Failure Association of the European Society of Cardiology

Editors: Seferovic P, Coats AJ, Rosano G, Anker SD

Publisher: Oxford Medicine

4. Title Chapter: Implantable Cardioverter Defibrillators

Authors: **Savarese G**, Linde C and Dickstein K

Book Title: HFA textbook of Heart Failure (in press) – Textbook on heart failure produced by the Heart Failure Association of the European Society of Cardiology

Editors: Seferovic P, Coats AJ, Rosano G, Anker SD

Publisher: Oxford Medicine

5. Title Chapter: Clinical trial design and interpretation

Authors: **Savarese G**, Polovina M, Filippatos G, Vaduganathan M

Book Title: HFA textbook of Heart Failure (in press) – Textbook on heart failure produced by the Heart Failure Association of the European Society of Cardiology

Editors: Seferovic P, Coats AJ, Rosano G, Anker SD

Publisher: Oxford Medicine

ACTIVITY AS REVIEWER AND EDITOR FOR PEER-REVIEWED JOURNALS

Serving as reviewer for international evaluations

- Reviewer for case reports submitted to the Heart Failure and the World Congress on Acute Heart Failure (HFA) 2016
- Reviewer for case reports submitted to the Heart Failure and the World Congress on Acute Heart Failure (HFA) 2017
- Member of the European Society of Cardiology (ESC) Abstract Reviewing Committee
- Member of the European Society of Cardiology (ESC) Abstract Reviewing Committee - 2018
- Member of the European Society of Cardiology (ESC) Abstract Reviewing Committee - 2019
- Reviewers for abstracts submitted to the Heart Failure and the World Congress on Acute Heart Failure (HFA) 2019
- Reviewers for abstracts submitted to the Heart Failure and the World Congress on Acute Heart Failure (HFA) 2020
- Reviewers for abstracts submitted to the Heart Failure and the World Congress on Acute Heart Failure (HFA) 2022

Editor of scientific journals

- Associate Editor European Journal of Heart Failure
- Academic Editor of Plos One
- Section Editor for heart failure for European Heart Journal – Open
- Deputy Editor of European Heart Journal - Case Reports
- Section Editor – European Cardiology Reviews

Member of an editorial board

- European Journal of Heart Failure
- European Heart Journal – Case Reports
- Cardiology and Therapy
- European Cardiology Review

Referee for scientific journals

- Reviewer for Nature Medicine
- Reviewer for Journal of American College of Cardiology
- Reviewer for Circulation
- Reviewer for European Heart Journal
- Reviewer for European Journal of Heart Failure
- Reviewer for Circulation: Heart Failure
- Reviewer for Annals of Internal Medicine
- Reviewer for International Journal of Cardiology
- Reviewer for Journal of Cardiovascular Medicine
- Reviewer for Journal of Cardiac Failure
- Reviewer for European Heart Journal - Cardiovascular Pharmacotherapy
- Reviewer for American Journal of Cardiology
- Reviewer for European Heart Journal – Case Reports

- Reviewer for European Cardiology Review
- Reviewer for Nutrition, Metabolism and Cardiovascular diseases
- Reviewer for European Journal of Cardiovascular Nursing
- Reviewer for Cardiology and Therapy
- Reviewer ESC Heart Failure

Reviewer or advisor for other scientific bodies

- EMA (European Medicines Agency) – AIFA (Italian Drug Agency)
- Clinical Event Adjudication (CEA) for DAPA-MI, DAPA-HF, DAPA-CKD, REVASC-MI, SPIRRIT-HFpEF – Uppsala Clinical Research Center, Uppsala, Sweden.
- Reviewer for Italian Ministry of education, university and research- funded projects
- Innovational research grant 2018. Netherlands Organization for Scientific Research
- Reviewer for the Deutsche Forschungsgemeinschaft (DFG)
- Netherlands Organisation for Scientific Research - Innovational research grants (VIDI)
- Reviewer for research grants in the United Arabic Emirates
- Reviewer for grants for the British Heart Foundation

Stockholm, February 5th 2025